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ABSTRACT 
Josetta Lynn Houlihan 
THE ROLE OF HSPs IN MHC CLASS II PRESENTATION OF SELECT ANTIGENS 
 
The function of major histocompatability complex (MHC) class II molecules is to present 
antigenic peptides to CD4+ T cells.  Typically, MHC class II molecules present peptides 
derived from exogenous sources.  Yet, certain endogenous antigens (Ags) have been 
found to be presented by class II molecules. Studies suggest that specific heat shock 
protein family members may play a role in Ag processing and subsequent class II 
presentation.  The studies presented here using B lymphoblasts demonstrate the 
importance of HSP90α, HSP90β, and possibly HSP70 in selectively regulating MHC 
class II presentation.   
 
Inactivation of HSP90 function using pharmacological inhibitors inhibited class II 
presentation of exogenous and endogenous GAD, but did not perturb the presentation of 
several other intra- and extracellular Ags.  Individual knockdown of HSP90 isoforms 
using isoform specific siRNA selectively inhibited GAD Ag presentation.  These results 
demonstrate a requirement for HSP90α and HSP90β in regulating MHC class II 
presentation of select Ags.   
 
Studies to explore mechanistically the roles of HSP90α and HSP90β in regulating GAD 
Ag presentation were pursued.  The pathways of exogenous and endogenous MHC class 
II presentation of GAD Ag are distinct yet converge with shared terminal processing of 
GAD within endosomal/lysosomal vesicles.  The effect of HSP90 manipulation on 
various shared components of the MHC class II pathway was examined.  The studies 
presented here suggest that HSP90α and HSP90β regulate MHC class II presentation of 
GAD Ag at discrete steps most likely involving HSP90 binding to GAD Ag rather than 




Studying the role of HSP90 in MHC class II presentation in B cells revealed the potential 
requirement for HSP70 in the presentation of select Ags.  The studies presented here 
demonstrate a possible role for HSP70 in the presentation of Ags such as SMA or Ig 
kappa by MHC class II molecules. 
 
Also included in this work is a study of a rare case of diabetes caused by type B insulin 
resistance due to development of insulin receptor autoantibodies during the treatment of 
hepatitis C with interferon alpha and ribavirin.  Clinical and laboratory findings in the 
case are presented.   
                                                        
                                          
                                                                                                 Janice S. Blum, Ph.D. 
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INTRODUCTION 
The immune system 
The human body is constantly challenged by numerous foreign agents such as bacteria, 
viruses, fungi, and parasitic worms.  Some of these invading microorganisms are 
infectious or pathogenic, and their own survival can lead to the death of the individual 
host.  To ensure protection from these invading pathogens, the human body has evolved a 
defense network known as the immune system to identify and destroy potential threats.  
The immune system consists of multiple, biological effector mechanisms, but is generally 
divided into two branches, the innate immune system and the adaptive immune system.   
 
The innate immune system is widely known as the first line of defense against invading 
pathogens.  A foreign invader first encounters the host’s barrier defenses, which are key 
to innate immunity.  Most simply, structures such as the skin and mucous coated 
membranes provide a physical barrier which the invading agent must breach to gain entry 
into the body.  Additionally, the innate immune system employs chemical barriers to 
disarm disease causing agents.  In the stomach, gastric acid lowers the pH and inhibits the 
growth of many microorganisms while lysozyme in mucous, tears, and saliva can damage 
bacterial cell walls.  If pathogens do breach the body’s physical and chemical barriers, the 
innate immune system can launch an immediate, but non-specific response.  Immune 
cells such as natural killer (NK) cells, macrophages, and neutrophils are recruited to the 
primary infection site.  These cells function to capture and destroy invading pathogens as 
well as to clear damaged or infected host cells.  These innate immune cells can efficiently 
clear pathogens or keep them in check until more specialized reinforcements arrive.   
 
Following the action of the innate response, the more specialized cells of the adaptive 
immune system are recruited.  A hallmark of the adaptive immune system is the ability to 
recognize antigens (Ags) found on or within pathogens.  One group of specialized cells of 
the adaptive immune system responsible for this pathogen specific recognition are called 
lymphocytes.  Lymphocytes are divided into B and T cells based on their distinct 
locations for development and their response to internal and external signals.  Both B and 
T cells recognize specific pathogenic targets via cell surface receptors.  The B cell 
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receptor is a cell surface bound antibody (Ab) and can recognize either whole or 
processed Ag.  In contrast, the T cell receptor can only recognize processed Ags when 
coupled with a self major histocompatability complex (MHC) molecule.  
 
 B cells function as professional antigen presenting cells (APCs), processing whole Ag 
into antigenic fragments and displaying those fragments via MHC molecules to T cells.  
In addition to Ag processing and presentation, B cells are responsible for Ab secretion.  
Secreted Abs identify and neutralize extracellular foreign Ags or tag them for attack by 
other immune cells.  B cells also play key roles in the memory response to Ags.  Upon 
pathogenic infection, certain memory B cells are generated and retained in the body after 
the infection is cleared.  Each memory B cell recognizes antigenic epitopes on a specific 
pathogen.  Upon re-infection with that same pathogen, subsets of memory cells 
recognizing these epitopes will rapidly proliferate and differentiate into effector cells able 
to rapidly clear the pathogenic infection (1).     
 
T cells are key players in the immune response functioning in Ag recognition, targeted 
cell destruction, and regulating the immune system.  T cells are further divided into two 
major groups, CD4+ and CD8+ T cells, based on their surface co-receptors.  Both these 
groups recognize their target antigenic peptides in the context of different classes of 
MHC molecules.  Naïve CD4+ T cells recognize specific antigenic peptides in the 
context of MHC class II molecules, while CD8+ T cells recognize specific antigenic 
peptides in the context of MHC class I molecules.  Upon antigenic recognition, naïve 
CD4+ T cells differentiate into effector CD4+ T cells.  As effector cells, CD4+ T cells 
secrete cytokines that stimulate B cells to differentiate and produce specific antibodies 
against extracellular pathogens and activate macrophages to specifically kill infected 
cells.   Effector CD8+ T cells are cytotoxic T cells that search for and kill infected cells.  
 
Two other types of APCs that play critical roles in the immune system are known as 
dendritic cells (DCs) and macrophages.  Macrophages are a key component of the innate 
immune system.  They are widely distributed in the body and are immediately available 
to combat a variety of pathogens without requiring prior exposure.  At the site of 
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infection, they function as key APCs, initiate inflammation, and recruit additional 
immune cells.  DCs play a key role in bridging the gap between innate and adaptive 
immunity.  Immature DCs migrate from the blood into various tissues and specialize in 
phagocytosis.  When they encounter an Ag, they rapidly mature and migrate to lymphoid 
tissues where they specialize in Ag presentation to T cells.   
 
Autoimmune type I diabetes and GAD 
The goal of the immune system is to protect and defend the human body from foreign 
invaders.  This requires the ability to distinguish self from non-self.  However, sometimes 
the immune system loses this ability and begins to recognize self Ags as non-self, 
resulting in the body attacking itself.  This loss of self-recognition results in the 
development of autoimmunity.  Currently, there are over 70 autoimmune diseases 
ranging from well known disorders such as multiple sclerosis to lesser known diseases 
such as scleroderma.  Interestingly, studies show that autoimmune diseases are much 
more common among women than men (2).  Research has yet to determine the exact 
events that result in the loss of self-tolerance and the development of autoimmune 
diseases.  Studies suggests that there are genetic components involved, as well as the 
possibility of microbial triggers (3, 4).   
 
Type I diabetes (TID) is one of the most common autoimmune disorders affecting 
approximately 1 in every 300 children (5).  The rising incidence of TID worldwide 
suggests the need for a better understanding of the pathogenesis of TID in order to 
develop prevention and treatment strategies.  Current studies are attempting to develop 
cell based therapies based on either replacement of pancreatic islet cells with islet-like 
cells derived from embryonic or adult stem cells or re-establishing immunological 
tolerance to self Ags using regulatory T cells and other tolerance promoting cells (6).  
The only effective therapy available involves the lifetime requirement for daily injections 
of exogenous insulin, which treats the symptoms of the disease, but is not a cure.  An 
alternative therapy is whole pancreas or islet transplantation, but this treatment is 
reserved only for severely ill patients and does not typically cure disease.   
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TID is characterized by the selective destruction of the insulin-producing, pancreatic β 
cells by the body’s own immune system.  The pathogenesis of TID has been extensively 
studied; however, the exact mechanisms involved in the initiation and progression of the 
disease is unclear.  One hallmark of disease progression is the presence of insulitis, the 
infiltration of the pancreas by immune cells.  Animal studies indicate that macrophages 
and DCs are among the first infiltrating cells (7).  Autoreactive CD4+ and CD8+ T cells 
have also been shown to infiltrate the pancreatic β cells and mediate islet destruction (5, 
7-9).  One of the earliest signs of disease progression is the appearance of islet-reactive 
antibodies (10-12).  Studies have found B lymphocytes play an important role in the 
pathogenesis of TID, functioning as APCs in the autoimmune response to islet cell Ags 
(13).  In both rodents and humans, genetic susceptibility and also resistance to TID is 
strongly linked to the inheritance of certain MHC class II alleles (14).  However, it is still 
somewhat controversial whether resident as well as recruited MHC class II-positive cells 
function to present islet cell Ags in the islets of TID (14).      
 
Glutamic acid decarboxylase (GAD) has been identified as a key target autoantigen in the 
development of TID (10, 12).  GAD is an enzyme involved in the synthesis of gamma-
aminobuturic acid (GABA), a key downregulating neurotransmitter in the central nervous 
system.  There are two isoforms of GAD differentiated by their molecular weight, 
GAD65 and GAD67.  Both isoforms are detected in the brain, but GAD65 appears to be 
the predominant form within the pancreas.  Research has clearly determined the role of 
GAD and GABA in the brain, but the role of GAD in the pancreas has yet to be 
understood (10).  Within β cells and neural cells, the GAD protein associates with 
intracellular membranes due to palmitoylation occurring at the N-terminus (15).    
 
GAD was originally identified as a diabetes autoantigen when studies showed that 85% 
of newly diagnosed TID patients contain antibodies directed against this protein (16).  
Since this first observation, much research has focused on determining a role for GAD in 
TID.  Unfortunately, it is controversial as to how central a role GAD plays in TID 
pathogenesis.  Some studies in young NOD mice found that immunization with purified 
GAD65 protein can induce tolerance preventing insulitis and diabetes while 
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immunization with other autoantigens conferred only partial protection (17, 18).  
However, another study found that immunization with GAD Ag resulted in only delayed 
onset of diabetes (19).  Studies have identified specific epitopes within the GAD protein 
that are highly immunogenic and can activate T lymphocytes (20-22).  Moreover, GAD-
reactive CD4+ Th1 cells were shown to induce diabetes in NOD/SCID mice (23).  While 
the majority of studies conclude that GAD plays a key role in TID development, there are 
a few studies that suggest otherwise.  One study found isolated GAD-specific T cell 
clones that do not induce diabetes (24). Another study found in NOD mice that β-cell 
specific suppression of GAD expression prevented diabetes progression (25).  Moreover, 
an additional study found that even GAD65 knockout mice developed diabetes (26).  It 
has been speculated that the controversy in determining the importance of GAD in TID 
pathogenesis is due to differences in laboratory techniques, substrains of NOD mice, and 
the preparation of GAD Ag, GAD peptide, and GAD-reactive T cell clones (27).  
Although there are a few studies that disagree, a majority of studies support a role for 
GAD in TID.  However, the exact role GAD plays in pathogenesis has yet to be defined.     
 
Previous studies in our lab have found that GAD Ag can be processed and presented by B 
cells.  Current and future studies are focused on determining the molecular mechanisms 
involved in GAD Ag processing by B cells.  Understanding how APCs process and 
present GAD to CD4+ reactive T cells could provide clues as to how GAD is involved in 
TID.   
 
MHC class I and class II molecules 
MHC class I molecules are surface, transmembrane glycoproteins consisting of an α 
heavy chain associated with a small subunit known as β2 microglubulin (β2M) (Fig. 1).  
MHC class I molecules are expressed on all nucleated cells.  The peptide binding groove 
of MHC class I molecules is closed; thus the peptides presented by MHC class I 
molecules typically range between 8-12 amino acids in length.   There are two anchor 
residues within the binding groove located at the carboxyl terminus and at an internal 
residue (28).   
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MHC class II molecules are also transmembrane glycoproteins, but they are comprised of 
an α heavy chain and a β heavy chain (Fig. 1).  Unlike MHC class I molecules, MHC 
class II molecules are selectively expressed by only certain cell types.  Primarily, MHC 
class II molecules are expressed on professional APCs which include B cells, 
macrophages, and DCs.  However, their expression on additional cell types can be 
induced.  The binding groove of MHC class II molecules is open-ended allowing for the 
binding of longer peptides up to 24 amino acids in length (29). 
 
Figure 1.  The basic structure of MHC molecules.   Left, The MHC class I molecule is 
a heterodimer composed of a 45 kD α subunit consisting of 3 domains and a 12 
kD β2 microglobulin (β2M) subunit.  Within the α subunit, the N-terminus α1 and 
α2 domains form the membrane-distal region of the complex and the peptide 
binding groove.  The C-terminal α3 domain forms the membrane-proximal 
domain linked to the transmembrane, and cytoplasmic regions of the complex.  
Right, The MHC class II molecule is a heterodimer composed of a 33 kD α 
subunit and a 28 kD β subunit.  The peptide binding groove is formed by the N-
terminal regions of both subunits, α1 and β1 domains.  In contrast to MHC class I 
molecules, the C-terminal domains of both subunits, α2 and β2, are linked to the 
transmembrane and cytoplasmic regions of the MHC class II molecule.     
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In humans, both MHC class I and II molecules are encoded by genes within the MHC 
locus on chromosome 6.  Human MHC class I molecules are encoded by three 
predominant allele families:  HLA-A, HLA-B, and HLA-C.  Human MHC class II 
molecules are encoded by three sets of genes: HLA-DR, HLA-DQ, and HLA-DP.  MHC 
molecules are expressed in a co-dominant manner. The genes encoding the MHC 
molecules are the most polymorphic genes known to date with hundreds of alleles 
already characterized (30).  The polymorphism and co-dominant expression of MHC 
molecules results in great genetic diversity among humans with regards to their HLA 
type.   
 
Classical MHC class I and class II presentation pathways 
Classically, MHC class I molecules have been recognized as presenting peptides derived 
from intracellular sources.  A schematic representation of this pathway is depicted in 
Figure 2.  MHC class I heterodimers formed by the association of an α heavy chain and a 
small β2M subunit are assembled in the ER.  The α chain is partially folded and 
associated with calnexin until it binds the β2M subunit.  Upon formation of the MHC 
class I α:β2M heterodimer and release from calnexin, the complex binds to multiple 
chaperone proteins including calreticulin and ERp57 and is tethered to the transporter 
associated with antigen processing (TAP) via tapasin.  Concurrently, cytosolic proteins 
are degraded to peptides via the multicatalytic proteasome and other cytosolic proteases.  
Peptide fragments are then delivered into the lumen of the ER through TAP and 
selectively loaded onto MHC class I molecules.  Folding of the MHC class I molecule is 
completed upon peptide binding at the binding groove.  MHC class I:peptide complexes 
are then exported from the ER via the Golgi secretory pathway.  Once the complexes 
reach the cell surface, they can interact with surveying CD8+ T cells and initiate a T cell 
response.  Clonal expansion of specific CD8+ T cells results in the generation of 







Figure 2.  Classical MHC class I presentation of endogenous antigens.  Endogenous, 
cytoplasmic Ags are digested into antigenic peptide fragments by cytoplasmic 
proteases such as the proteasome.  The antigenic peptides generated are 
transported into the ER by TAP1/2 heterodimers.  With the help from additional 
ER proteins such as tapasin, calreticulin, and Erp57, these peptides are loaded 
onto the peptide binding grooves of MHC class I molecules.  MHC class I:peptide 
complexes dissociate from these ER proteins, transit through the Golgi secretory 
network, and are displayed on the cell surface for screening by circulating CD8+ 
T cells.   
 
In contrast to MHC class I molecules, MHC class II molecules classically present 
peptides derived from extracellular sources.  Figure 3 schematically depicts this classical 
pathway.  DCs and macrophages internalize extracellular pathogens by either pinocytosis 
or phagocytosis while B cells internalize extracellular pathogens by either receptor 
mediated endocytosis or less efficiently, pinocytosis.  Once internalized, extracellular 
Ags transit through the endosomal/lysosomal network from early to late endosomes, 
lysosomes, and the MHC class II rich compartment (MIIC).  Within these low pH 
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compartments, engulfed Ags are degraded by various proteases and denaturing reactions 




Figure 3.  Classical MHC class II presentation pathway.  Exogenous Ags are 
internalized by APCs and degraded into peptide fragments while they are sorted 
through the endosomal/lysosomal network.  MHC class II molecules are 
assembled in the ER and associated with the chaperone invariant chain (Ii).  MHC 
class II:Ii complexes transit through the secretory network.  During transit, Ii is 
sequentially degraded into smaller peptide fragments, ultimately leaving the final 
CLIP fragment in the peptide binding groove of MHC class II molecules.  
Vesicles from the endosomal/lysosomal network containing antigenic peptide 
fragments fuse with secretory vesicles containing MHC class II:Ii complexes, 
resulting in the formation of MHC class II containing compartments (MIIC).  In 
this compartment, HLA-DM and HLA-DO catalyze the dissociation of CLIP 
fragment and the loading of antigenic peptide onto MHC class II molecules.  
MHC class II:peptide complexes continue to transit to the cell surface to be 
displayed to circulating CD4+ T cells.  
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In the ER, newly synthesized MHC class II α and β chains are assembled into 
heterodimers.  The chaperone molecule invariant chain (Ii) associates with the MHC 
class II dimers and performs various chaperone functions (37, 38).  The physical binding 
of Ii within the peptide binding groove of the MHC class II dimers prevents premature 
peptide loading of the dimers.  A targeting sequence within the cytoplasmic tail of Ii 
guides the Ii:MHC class II complexes to the secretory pathway and mediates intracellular 
sorting.  While progressing through the secretory network, Ii undergoes stepwise 
degradation by proteases to a final fragment called the class II-associated invariant chain 
peptide (CLIP), which remains associated with the MHC class II peptide binding groove 
(31, 39-47).  A schematic of Ii degradation is shown in Figure 4.  When MHC class 
II:CLIP complexes reach the MIIC compartment, the non-classical class II  molecule 
HLA-DM  catalyzes the removal of CLIP from the peptide binding groove and the 
capture of an antigenic peptide by a MHC class II molecule (39, 42, 43, 48-51).   HLA-
DM activity is regulated by its interaction with another non-classical class II molecule 
HLA-DO (51-55).   A schematic of the activity of HLA-DM and HLA-DO in the removal 
of CLIP and peptide loading of MHC class II molecules is depicted in Figure 5.  MHC 
class II molecules have been found to bind to peptides at different points in the 
endosomal pathway; however, the major point of association appears to be in the MIIC, a 
mature endosomal or prelysosomal vesicle (39).  The MHC class II:peptide complex is 
then trafficked to the cell surface where it can be surveyed by CD4+ T cells resulting in T 
cell activation and an immune response (31, 39-44, 47-49).  Recycling of MHC class 
II:peptide complexes can occur by reinternalization of surface MHC class II:peptide 
complexes via the endocytic network.  Within recycling early endosomes, MHC class II 
molecules can exchange their peptides for new peptides, resulting in further 










Figure 4.  Schematic of Ii processing in B cells.  In B cells, Ii binds to MHC class II 
molecules in the ER and chaperones MHC class II dimers as they transit through 
the secretory network.  During transit, Ii is sequentially degraded into smaller 
peptide fragments.  The C-terminal of Ii is cleaved leaving the leupeptin induced 
peptide, LIP.  Further processing on the C-terminus cleaves LIP into the small 
leupeptin induced peptide, SLIP.  Ultimately, the N-terminus anchoring Ii to the 
vesicle membrane is cleaved resulting in the final Ii fragment called class II-
associated invariant chain peptide, CLIP.  CLIP remains in the MHC class II 






Figure 5.  Schematic of HLA-DM and HLA-DO function in B cells.  In the MIIC, 
HLA-DM functions to remove CLIP from the MHC class II binding groove and 
facilitate the binding of antigenic peptides. HLA-DO regulates the activity of 
HLA-DM.   
 
MHC class II presentation of cytoplasmic Ags 
Classically, MHC class I and class II molecules were viewed as having distinct and non-
overlapping functions with MHC class I molecules presenting peptides derived from 
intracellular Ags and MHC class II molecules presenting peptides derived from 
internalized, extracellular Ags.  In recent years, it has been determined that there is 
significant crosstalk between these two classical pathways of Ag presentation.  It has 
been well established that MHC class I molecules can present peptides derived from 
exogenous sources by a process called cross-presentation (59, 60).  It is also well 
established that that MHC class II molecules are capable of binding peptides derived 
from endogenous sources and presenting them to CD4+ T cells (36, 47, 61-74).   
 
Biochemical approaches such as peptide-elution from MHC class II molecules in 
combination with peptide sequencing via tandem mass spectrometry have detected MHC 
class II ligands originating from endogenous proteins.  While the majority of these 
cytoplasmic peptides are derived from endogenous proteins found at the cell surface or 
within endocytic and secretory vesicles, a significant number were found to originate 
from cytosolic proteins (36, 47, 61-74).  Analysis of the peptides bound by MHC class II 
molecules in mice also revealed the presence of many cytosolic-derived epitopes.  One 
such study found the majority of MHC class II ligands to be derived from self-proteins 
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such as transmembrane and secretory proteins.  However, 21% of the ligands detected 
were peptides derived from cytosolic proteins such as actin, tubulin, and 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) (68).  Another study in human B 
cells detected greater than 85% of the MHC class II ligands to be derived from 
endogenous proteins including cytosolic proteins (75).     
 
Additionally, studies with viruses and tumor cells have also shown that epitopes from 
cytoplasmic Ags access MHC class II molecules and trigger T cell responses (61, 73, 74, 
76, 77).  Viral Ags such as the matrix and nucleocapsid proteins from the measles virus 
and the M1 matrix protein of the influenza virus were all shown to be presented by MHC 
class II molecules, and viral-specific T cell responses were detected (78, 79).  Epitopes 
derived from two different human melanoma tumor Ags, a mutated form of the human 
melanoma Ag CDC27 and a mutated version of triosephosphate isomerase, were both 
detected as ligands for MHC class II-restricted presentation and recognized by tumor 
specific CD4+ T cells (77).  Studies also suggest that during T cell development in the 
thymus, MHC class II restricted presentation of cytosolic Ags is a requirement for 
complete elimination of autoreactive T cells.  For example, in mice transgenic for either 
endogenous or cell surface pigeon cytochrome c, both forms of the Ag were presented by 
MHC class II molecules and induced CD4+ T cell tolerance (80).     
 
Many cell types appear capable of presenting cytoplasmic Ags via MHC class II 
molecules.  To date, B cells, DCs, MHC class II-transfected tumor and epithelial cells, 
thymic epithelial cells (TECs), and myeloid progenitor cells have all been shown to 
present cytoplasmic Ags via MHC class II molecules.  However, these different cell types 
vary in their epitope repertoire as well as their efficiency of cytoplasmic Ag presentation.  
 
Functional and biochemical studies have found that depending upon the specific HLA-
DR allele analyzed, the contribution of cytosolic peptides to the ligand repertoire varies 
(61, 65, 67, 75, 77, 78, 81-83).  Moreover, not all cytoplasmic proteins appear to be a 
source of MHC class II peptide ligands (66, 78, 84).   For example, endogenously 
synthesized membrane associated viral glycoprotein (GP) from the lymphocytic 
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choriomeningitis virus (LCMV) can be efficiently presented by MHC class II molecules, 
but the LCMV nucleoprotein (NP) cannot (66).  Moreover, in vivo studies with LCMV 
infected animals determined that CD4+ T cells can recognize LCMV-GP, but not 
LCMV-NP (84).     
 
Taken together, it appears that MHC class II molecules have evolved mechanisms to 
sample select antigenic peptides from the cytoplasm and present them to CD4+ T cells in 
order to enhance helper T cell responses to intracellular pathogens and tumors and to 
maintain self tolerance (61, 66, 67, 69, 73, 74, 77, 80).  However, the mechanisms 
involved in cytoplasmic Ag presentation by MHC class II molecules remain rudimentary.   
 
Possible pathways of MHC class II presentation of endogenous Ags 
Endogenous Ags may access MHC class II molecules for presentation to CD4+ T cells 
via different routes.  One possibility is that endogenous Ags may be released during cell 
death and presented by bystander APCs via the classical MHC class II pathway (Fig. 3).  
While studies have shown that APCs can present Ags released from apoptotic or lysed 
cells, studies also suggest few cytoplasmic epitopes are released by viable cells (67, 69, 
70, 74, 85).   This pathway may be engaged during cytopathic viral infections when 
damage and death of infected cells are quite common.  Another possible route is via 
autophagy which involves the sequestering of cytoplasmic and nuclear Ags into 
autophagosomes prior to Ag processing and MHC class II presentation (Fig. 6).  Bulk 
autophagy can be subdivided into two types of autophagy, macroautophagy and 
microautophagy, distinguishable by chemical inhibitors and microscopy.  In 
macroautophagy, ER membranes bud and randomly enclose nuclear and cytoplasmic 
material within vacuoles termed autophagosomes that eventually fuse with lysosomes for 
content degradation.  While macroautophagy can occur at low levels in healthy cells, it 
can be up-regulated with serum starvation (86).  In contrast, microautophagy has only 
been observed in yeast and is regulated by starvation.  This pathway involves the direct 
sequestering of proteins into lysosomes for protein degradation.  The role of 
macroautophagy in MHC class II presentation is controversial.  Some studies using 
chemical agents blocking macroautophagy suggest that macroautophagy is involved in 
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the MHC class II presentation of some nuclear and cytoplasmic Ags (74, 83, 87).  
However, other studies found MHC class II presentation of cytoplasmic Ags unaffected 
by inhibition of macroautophagy (69, 70, 73, 85).  A third possible route of MHC class II 
presentation of endogenous Ags  involves the processing of cytoplasmic Ags within the 
cytoplasm and the selective translocation of the resulting cytoplasmic peptides into MHC 
class II-rich organelles (Fig. 6).  Chaperone proteins direct the processing and 
translocation of Ags through this pathway; thus, the pathway is termed chaperone 
mediated autophagy (CMA).  
 
Figure 6.  Alternative pathways of MHC class II presentation of cytoplasmic Ags.  
Endogenous, cytoplasmic Ag can gain access to the MHC class II machinery via 
different routes of autophagy.  In macroautophagy, ER membranes bud and 
randomly enclose cytoplasmic material forming intracellular vesicles called 
autophagosomes.  Autophagosomes can directly fuse with lysosomes, empting 
their contents into the lysosomes for degradation.  In microautophagy, random 
cytosolic proteins are directly sequestered into the lysosomes for protein 
degradation by lysosomal proteases.  In contrast, selective degradation of 
cytosolic proteins occurs in chaperone mediated autophagy (CMA).  Two 
proteins, lamp2 and HSC70, have been shown to play critical roles in this 
pathway by facilitating entry of antigenic peptides into the lysosomes.     
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Key players in MHC class II presentation 
Invariant chain (Ii)   
As mentioned previously, it is well established that Ii functions as an MHC class II 
chaperone by facilitating proper MHC class II αβ folding, stabilizing and targeting dimers 
through the secretory network, and preventing premature peptide loading.  Research 
suggests Ii expression alters MHC class II expression.  Ii deficiency in Ii knockout mice 
resulted in low MHC class II expression in APCs (37, 88).  Loss of Ii chain in NOD mice 
resulted in decreased surface MHC class II expression and the retention of MHC class II 
aggregates in the ER (89).    
 
Studies suggest that Ii plays a role in MHC class II presentation of exogenous and 
endogenous Ags.  Our lab recently implicated Ii in MHC class II recycling and peptide 
presentation (90).  APCs from Ii knockout mice exhibited decreased exogenous Ag 
presentation, but enhanced presentation of peptides due to their ability to bind directly to 
MHC class II molecules (91).  Studies in Ii transfected fibroblast cells also correlated Ii 
expression levels with Ag presentation; the amount of exogenous Ag required to induce a 
T cell response was inversely correlated with the level of Ii expression (92).  However, 
low Ii expression is thought to promote the presentation of endogenous Ags.  The 
presentation of a cytosolic peptide from the influenza virus matrix protein was efficiently 
presented by Ii deficient cells and inhibited by the expression of Ii (79).  MHC class II 
expressing myeloid progenitor cells are efficient at presenting cytosolic peptides (81).  
Another study found that loss of Ii in MHC class II cancer vaccines resulted in enhanced 
activation of tumor reactive T cells (93).    
 
Alterations in Ii expression have been shown to alter the immune response.  In mice, Ii 
deficiency altered the Th-2 immune response resulting in a preferential Th-1 immune 
response (94).  Another study found Ii deficient mice to have an impaired ability to 
mount cellular and humoral immunity upon viral infections (95).  Ii may play a role in the 
development of autoimmunity as suggested by the finding that loss of Ii in NOD mice 
prevented the onset of TID (96).    
 17 
While Ii expression is typically linked to MHC class II expression and function, there are 
some circumstances where this is not the case.  There is evidence that MHC class II 
proteins are expressed even in the absence of Ii (89, 97-101).  This may reflect that 
different MHC class II alleles are more or less dependent on Ii expression as well as 
variation in MHC class II biosynthesis in different cell types.  Studies suggest the 
existence of Ii independent pathways of MHC class II presentation (102).  Ii deficiency in 
NOD mice did not substantially alter Ag presentation.  Yet, taken together, studies 
overall suggest that regulation of Ii expression may provide a way to modulate MHC 
class II Ag presentation.  Thus, understanding the role of Ii in MHC class II presentation 
may prove important for the development of novel immunotherapeutics against malignant 
diseases, viral infections, as well as autoimmune disorders.   
 
Cathepsins 
The endosomal/lysosomal network contains numerous hydrolases including proteases. 
The most well known endosomal/lysosomal proteases are the cathepsins.  In humans, 
there are 11 known cysteine proteases, cathepsins B, C, F, H, K, L, O, S, V, X, and W.  
There are also three aspartic proteases, cathepsins D, cathepsin E, and AEP, and one 
serine protease, cathepsin G.  Cathepsin family members have been shown to be involved 
in numerous biological functions including the immune response and Ag processing 
(103).  Cathepsins B, C, D, X, H, L, and S have all been shown to have clear roles in the 
immune system, and cathepsins S and L are the only ones shown to have non-redundant 
roles (103).  In general, these cysteine proteases are optimally active within the slightly 
acidic, reducing environment of endosomes and lysosomes.   
 
Cathepsin S is primarily expressed in phagocytic APCs and is believed to be the major 
cysteine protease involved in MHC class II Ag processing and presentation (104-106).  
Various studies in cathepsin S null mice support this theory.  The APCs from cathepsin S 
deficient mice exhibited a severe decrease in Ii degradation and alterations in MHC class 
II-bound Ii fragments and MHC class II presentation of exogenous Ags (46, 107).   
Inhibition of cathepsin S in B cells prevented complete proteolysis of Ii (44).  Studies 
also found cathepsin S to be required for the normal trafficking, maturation, and peptide 
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loading of MHC class II molecules (108, 109).  Inhibition of cathepsin S with small 
molecule inhibitors resulted in diminished Ag presentation by MHC class II molecules 
(104, 107).  Cathepsin S deficiency has also been shown to decrease the presentation of 
certain epitopes, suggesting that cathepsin S can directly affect the processing of select 
Ags (107, 110).  In contrast to other cathepsins, cathepsin S retains considerable stability 
and proteolytic activity over a broad pH range, functioning in both endosomes and 
lysosomes (103, 109, 111, 112).  In human DCs and B cells, the selective inhibition of 
cathepsin S resulted in the accumulation of incompletely processed Ii fragment, 
suggesting that cathepsin S plays a non-redundant role in Ii processing (44, 113).  While 
studies have analyzed various Ii fragments, the exact cathepsin S cleavage sites on Ii 
were unknown until recently (114).  This discovery may prove helpful in identifying 
cathepsin S cleavage sites within Ags and determining the relevance of this protease in 
generating antigenic peptides for MHC class II presentation.  Studies also suggest that 
cathepsin S is an immunomodulator of immune diseases such as rheumatoid arthritis and 
bronchial asthma; thus, cathepsin S inhibitors are currently being evaluated as potential 
therapeutics for certain immune disorders (115, 116).    
 
Cathepsin L is primarily expressed in cortical thymic epithelial cells (cTECs) and 
minimally in professional APCs.  Cathepsin L deficient mice exhibit decreased numbers 
of CD4+ T cells and defective Ag presentation by MHC class II molecules in their cTECs 
due to incomplete Ii processing (45).  Thus, cathepsin L is thought to regulate positive 
selection in the thymus.  Additional studies identified cathepsin L as an essential enzyme 
for the development of TID in NOD mice (117).  Studies suggest that Cathepsin L 
mediates the final cleavage of Ii to the CLIP fragment (40, 103).  As shown with 
cathepsin S, cathepsin L deficient APCs show decreased Ag presentation of select Ags. 
This suggests that like cathepsin S, cathepsin L may also mediate MHC class II 
presentation of select Ags (110).  Interestingly, a splice variant of Ii, p41, has been shown 
to inhibit cathepsin L activity, suggesting a negative feedback control mechanism (112).     
 
Studies from our own lab and others suggest a role for the cathepsins B and D in both Ii 
processing and MHC class II presentation (35, 67, 118-120).  Treatment of APCs with 
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specific cathepsin B and D inhibitors resulted in decreased Ag presentation and Ii 
expression (35, 118, 119).  Treatment of B cells with cathepsin B inhibitor II slightly 
inhibited both endogenous and exogenous GAD presentation, while treatment with a 
cathepsin D inhibitor only altered exogenous GAD presentation (67).  Our results suggest 
that cathepsins B and D may play roles in endogenous and exogenous GAD Ag 
presentation by MHC class II molecules.  Recent studies found activation of cathepsin D 
to be required for the processing and presentation of a mycobacterial Ag in macrophages 
(120).  However, some evidence suggests their activity may be redundant and dispensable 
for MHC class II presentation.  One study found that cathepsin B and D deficiency in 
knockout mice only moderately shifted the efficiency of Ag presentation of select 
epitopes, but did not perturb the overall capacity of APCs (121).  Another study found 
cathepsin D deficiency actually enhanced the presentation of certain peptides and 
suggests some redundancy among the lysosomal proteases (122).  Taken together, these 
results suggest that like cathepsin S, cathepsin B and D may be required for the 
presentation of select Ags for MHC class II presentation.   
 
Asparagine endopeptidase (AEP)  
 AEP is an asparagine-specific cysteine protease found within endosomes and lysosomes.  
Although it is a cysteine protease, AEP is not grouped with cathepsins S and L as it is 
homologous with the caspases (123).  Unlike the other lysosomal cysteine proteases, AEP 
is leupeptin insensitive (124, 125).   Evidence suggests that AEP is involved in MHC 
class II presentation.  In B cells, AEP was found to initiate the processing of the 
exogenous Ag tetanus toxin (125).  Moreover, disruption of a single AEP cleavage site in 
the microbial Ag tetanus toxin C fragment resulted in a dramatic decrease in its ability to 
be processed and presented to T cells (126).  The role of AEP in Ii processing remains 
controversial.  A study with B cell lines and monocyte-derived DCs showed that AEP can 
initiate Ii processing and that inhibition of AEP results in delayed Ii processing (127).  
However, another study in AEP-deficient mice found Ii processing, MHC class II 
maturation, and Ag presentation unaffected by AEP deficiency (128).    
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AEP activity has been linked to autoimmunity as well as to neuronal injury during 
neuroexcitotoxicity or ischemia.  In reference to autoimmunity, studies found an AEP 
processing site within the myelin basic protein (MBP) autoantigen.  Moreover, the 
presentation of MBP was found to be inversely proportional to the amount of cellular 
AEP activity. It is suggested that the destruction of epitopes within MBP may limit its 
display in the thymus and prevent central tolerance to this autoantigen (129).  A current 
study found AEP to play a crucial role in mediating kainic acid or stroke elicited 
neurotoxicity (130).  In this study, AEP was found to be activated under acidic 
conditions, responsible for the cleavage of neuronal protein, and the cause of DNA 
damage in the brain.  Thus, understanding the role of AEP may have implications on 
immune tolerance and neuronal cell death.   
 
HLA-DM and HLA-DO 
Our lab and others have found HLA-DM and HLA-DO to play critical roles in MHC 
class II mediated Ag presentation in APCs.  HLA-DM is mainly localized in the 
endosomal/lysosomal vesicles of APCs (51).  In these compartments, HLA-DM assists 
the peptide loading of MHC class II molecules by catalyzing the exchange of CLIP for 
antigenic peptide fragments within endocytic compartments (39, 42, 43, 48-51).   
Additionally, HLA-DM edits the repertoire of peptides loaded onto MHC class II 
molecules by preferentially loading peptides with high affinity to MHC class II (51).  
Studies in mice with an HLA-DM deficiency in APCs resulted in almost all the surface 
MHC class II molecules loaded with CLIP (131).  Studies in our lab found that MHC 
class II presentation of endogenous and exogenous GAD was affected by the expression 
level of HLA-DM; high HLA-DM levels inhibited GAD presentation (132).  The 
function of HLA-DO is still controversial as it may function as a positive or negative 
regulator of HLA-DM (51-55).  Studies also suggest that HLA-DM and HLA-DO 
function may have implications in autoimmune disorders (133).  Certain MHC class II 
alleles confer protection and susceptibility to certain autoimmune disorders.  It is 
suggested that this is possibly due differences in MHC class II affinity for CLIP and 
peptides.  Since HLA-DM and HLA-DO regulate the binding and release of CLIP based 
on MHC class II affinity, manipulation of HLA-DM and HLA-DO function is considered 
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a possible therapeutic target. Taken together, studies suggest that HLA-DM and HLA-
DO function together to influence the repertoire of epitopes presented by MHC class II 
molecules.  
 
Cytoplasmic proteases:  proteasome and calpain 
 While exogenous Ags are processed by proteases within endosomes/lysosomes for MHC 
class II presentation, cytoplasmic Ags for MHC class I presentation are primarily 
processed by the cytoplasmic protease proteasome within the cytosol.  Both cytosolic and 
endo/lysosomal proteases may be required for MHC class II presentation of endogenous 
Ags. Studies in our lab and others found Ag processing by cytoplasmic proteases to be a 
requirement for MHC class II presentation of cytoplasmic Ags (67, 69).  Treatment of 
PriessGAD B cells with chloroquine, an anti-malarial drug that raises the pH of 
endo/lysosomes, completely inhibited MHC class II presentation of exogenous GAD Ag, 
but only slightly decreased presentation of cytoplasmic GAD Ag (67).  Treatment of 
PriessGAD cells with calpeptin, an inhibitor of the cytoplasmic protease calpain, 
completely inhibited MHC class II presentation of cytosolic GAD Ag, but did not affect 
exogenous GAD Ag presentation (67).  Moreover, treatment with lactacystin or 
epoxomicin, proteasome inhibitors, selectively inhibited cytoplasmic GAD presentation 
(67 and data not shown).  MHC class II molecules have been shown to present peptides 
from Ags introduced into the cytosol via hyperosmotic lysis of pinosomes (69).  MHC 
class II presentation of these Ags was blocked by inhibition of the proteasome by 
inhibitors such as lactacystin (69).  Taken together, these results suggest that the 
cytoplasmic proteases calpain and the proteasome are required for MHC class II 
presentation of endogenous Ags.  However, further trimming of those peptides within the 
endosomes/lysosomes may also be required.   
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Heat shock proteins are potential players in MHC class II presentation 
Links between heat shock proteins (HSPs) and the immune system have been suggested.  
Roles for HSPs have been identified in immune responses, tumor surveillance, and Ag 
presentation (134-136).  Research by our laboratory and others suggests that HSPs can 
act as chaperones to facilitate Ag processing for MHC class I and II presentation (85, 
137-144).  HSPs are a group of highly conserved proteins that primarily serve as 
molecular chaperones.  They are grouped into families based on their molecular size, 
sequence homologies, and antigenic cross reactivities (145).  HSPs have been found to 
play various intracellular roles including assisting in protein folding, assembly, and 
degradation, scavenging for peptides produced during Ag proteolysis, and facilitating 
protein translocation (146-148).  The term HSP originated due to the inducibility of some 
of these proteins upon heat or cellular stress.  However, many of these proteins are 
expressed constitutively, sometimes at high levels, suggesting a critical role in the 
everyday functions of a cell (145).     
 
HSC70 
The constitutively expressed heat shock cognate protein HSC70, also known as HSC73, 
is a member of the HSP70 family and makes up 1% of the total cellular protein content 
(149).  Unlike other HSPs, HSC70 is only slightly induced by heat shock even though the 
gene contains functional heat-shock regulatory elements (150).  The structure of HSC70 
is typical of an HSP70 family member, an ATP-binding domain at the amino-terminus 
followed by a peptide binding domain in the middle (151).  The carboxyl-terminal 
domain provides binding sites for cofactors whose role is to modulate HSC70 activity 
(152).  HSC70 is depicted schematically with key protein domains labeled in figure 7.  
Like other HSPs, peptide binding by HSC70 is ATP-dependent; in the ATP bound state, 
HSC70 binds peptides, but upon ATP hydrolysis to ADP, HSC70 releases bound peptides 
(151).  HSC70 recognizes short peptide motifs with a minimal size of 5-7 residues via a 
ligand binding groove, but is preferential to ligands with hydrophobic and basic residues, 
originally termed the KFERQ motif (153, 154).  Further research has revised this 




Figure 7.  Schematic diagram of HSPs.  The structure of HSC70, HSP90, and HSP70 
are schematically represented above. The N-terminus of HSC70, HSP90, and 
HSP70 contains an ATPase domain. A peptide binding domain is located within 
the center of the HSC70, at the N-terminus of HSP90, and at the C-terminus of 
HSP70.  The C-terminus of HSP90 contains a dimerization domain, allowing the 
formation of HSP90 homodimers.         
 
Endogenous HSC70 is predominately localized in the cytoplasm (156).  In the cytosol, 
HSC70 operates as part of a molecular chaperone complex.  This complex includes 
cofactors such as Hip, Hop, HSP40, BAG-1, and HSP90.  Hip functions to stimulate the 
assembly of HSC70 with HSP40 and its substrate, while BAG-1 functions to uncouple 
the binding of substrate proteins from the ATPase cycle of HSC70 (157-160).   HSP40 
stimulates the ATPase activity of HSC70.  HSP90 is linked to HSC70 by the co-
chaperone Hop (157, 161).  HSC70 is also localized on the luminal and cytoplasmic face 
of endosomes and lysosomes (162, 163).  It is proposed that this localization allows 
HSC70 to assist in the transport of cytoplasmic peptides to these organelles (164).  While 
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luminal HSC70 does not associate with any of its cytoplasmic chaperones, HSC70 on the 
cytoplasmic face acts in concert with the lysosomal associated membrane protein-2a 
(lamp2a) (162, 163).  Lamp-2a is a transmembrane endosomal/lysosomal protein that 
assists in the translocation of peptides into lysosomes (165, 166).  Studies in our lab and 
others indicate that HSC70 is required for peptide transport into the lysosome (85, 163).  
Our lab has previously shown in B cells that alteration of either HSC70 or Lamp-2a can 
disrupt MHC class II presentation of numerous cytoplasmic autoantigens leading one to 
deduce that CMA may regulate immunity (85).    
 
HSP90 
HSP90 is also found within the cytoplasmic multi-chaperone complex (167).  HSP90 is a 
highly conserved, constitutively expressed cytosolic chaperone protein.  In eukaryotes, 
HSP90 is a critical protein chaperone as indicated by studies finding HSP90 null 
mutations lethal.  Under normal conditions, HSP90 constitutes 1-2% of the total cellular 
protein content, but under stressed conditions such as heat shock, HSP90 levels can 
increase to 4-6% (168).  HSP90 functions include controlling protein folding, turnover, 
and trafficking.  While HSP90 has been linked to almost 100 different client proteins, 
many of the known HSP90 substrates are signal transduction molecules such as the 
glucocorticosteroid receptor (143, 151, 168, 169).  Thus, the best characterized example 
of HSP90 chaperone activity is the HSP90 dependent signaling pathway of steroid 
hormone receptors (169).  Typically, HSP90 binds to client proteins that are in a near 
native state or late stages of folding, recognizing unfolded regions within the proteins 
(155, 170).  Like HSC70, HSP90 is an ATP-dependent chaperone in that HSP90 
chaperone activity requires both binding and hydrolysis of ATP (171-173).  The structure 
of HSP90 is similar to other HSPs and is depicted schematically in Figure 7 with key 
domains labeled.  The N-terminus houses the ATPase and peptide binding domains, a 
charged domain is in the middle, and a dimerization domain is found at the C-terminus 
(174).     
 
In the cell, HSP90 functions in a multi-chaperone complex in association with other heat 
shock proteins such as HSC70, HSP70, and HSP40 as well as co-factors such as BAG-1, 
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HOP, CHIP, and HIP (152, 167, 175, 176).  Through interactions with its co-factors, 
HSP90 is linked to the ubiquitin-proteasome pathway (152).  While HSP90 null 
mutations have proven lethal, conditional inhibition of HSP90 by the use of 
pharmacological inhibitors has proven useful in understanding HSP90 structure and 
function.  The benzoquinon ansamycin antibiotic geldanamycin (GA) and the 
macrocyclic drug radicicol (RA) are two such HSP90 inhibitors that bind to the ATP-
binding site of HSP90 and inhibit the ATPase activity of HSP90, thus inhibiting HSP90 
chaperone activity (177).     
 
In humans, HSP90 is expressed as two closely related isoforms, HSP90α and HSP90β, 
which are both constitutively expressed and induced by cellular stress (170, 174, 178).   
Assays using pharmacological inhibitors such as RA and GA fail to distinguish between 
the function of these two isoforms, with both proteins inactivated by these compounds 
(174).  Therefore, until recently, both isoforms were referred to simply as HSP90.  While 
both isoforms bind similarly to their intracellular co-chaperones, in some cases HSP90α 
and HSP90β were found to behave differently with respect to substrate interactions (178).  
HSP90 has been implicated in regulating both direct and cross-presentation pathways for 
MHC class I molecules.  HSP90 ligands include peptides which can bind MHC class I 
molecules, and inhibition of HSP90α expression disrupts cytoplasmic Ag presentation by 
MHC class I molecules (141).  HSP90 also appears to regulate human DC functions 
including cell maturation, MHC class I and II expression, and MHC class II presentation 
(143).  However, the role of HSP90 in MHC class II Ag presentation in B cells as well as 
the contribution of the individual HSP90 isoforms has yet to be determined.   
 
HSP90 has been shown to play a key role in chaperoning client proteins in a variety of 
cellular processes including cell proliferation, differentiation, and apoptosis (174).  
Manipulation of HSP90 activity has been used to modulate protein folding and to induce 
the proteolysis of misfolded or mutant proteins in a variety of disease conditions 
including a wide range of malignancies and neurological disorders including Alzheimer’s 
disease, Parkinson’s disease, autoimmune encephalomyelitis, and polyglutamine diseases 
(179-182).  HSP90 inhibitors have also been tested in human clinical trials to promote 
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tumor regression (181).  Studies also suggest that HSP90 and MHC class II presentation 
may play a role in TID.  B lymphocytes play an important role in the pathogenesis of 
TID, functioning as APCs in the autoimmune response to islet cell Ags such as GAD 
(13).  However, it is still somewhat controversial whether resident as well as recruited 
MHC class II-positive cells function to present β cell Ags in the islets of TID patients 
(183).  Notably, in TID, β cell stress results in an induction of HSP90 expression (184).  
An increase in select anti-HSP90 Ab isotypes has also been noted in type I diabetics and 
family members, suggesting the potential release of this HSP from cells (185).  Thus, 
understanding the role of HSP90 isoforms in MHC class II presentation may yield 
mechanistic insights regarding the presentation of autoantigens such as GAD.   
 
HSP70 
Another HSP found to interact with both HSP90 and HSC70 is HSP70.  HSP70 is an 
inducible HSP found in the cytosol and in lysosomal compartments (166).  As with 
HSC70 and HSP90, HSP70 also contains an amino-terminal ATPase subunit and a 
carboxyl-terminal peptide binding domain, as depicted schematically in figure 7 (186).  
HSP70 has been shown to perform a variety of cellular functions including stabilizing 
newly synthesized or unfolding polypeptides, facilitating translocation of nascent chains 
across membranes, mediating assembly or disassembly of multimeric protein complexes, 
and targeting proteins for degradation within lysosomes (187-189).  Due to its wide 
variety of functions, HSP70 recognizes and binds a wide variety of client proteins in a 
promiscuous manner.  However, studies suggest that HSP70 recognizes and binds 
hydrophobic regions of polypeptides that are typically buried within proteins and exposed 
during misfolding or denaturation (140, 153).    
 
In response to stress, HSP70 is secreted from a variety of cell types (190-195).  However, 
it is still controversial as to the mechanisms involved in the HSP70 secretion pathway.  
Some studies suggest that HSP70 is released by a non-specific process such as cell lysis 
while others suggest specialized membranes such as lipid rafts or exosomes are involved 
(190, 192, 193, 196).  Studies in tumor cells found that HSP70 was secreted by tumor 
cells through a pathway involving lysosomal endosomes (197).  Studies suggest that 
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extracellular HSPs including HSP70 may play important immunoregulatory functions 
(198-206).   For example, treatment of monocytes and DCs with recombinant HSP70 
stimulated cytokine production, upregulated co-stimulatory molecules, and enhanced 
MHC class II Ag presentation (200, 204).   
 
HSP70 has been highly studied as a key player in the pathogenesis of amyloidosis.  
Amyloidosis is a group of diseases characterized by the assembly of protein fibrils that 
are deposited extracellulary in various organs and tissues.  HSP70 has been shown to 
promote the proteasomal degradation of the proteins that make up these fibrils, 
potentially regulating fibril accumulation (207).  Studies have detected extracellular 
HSP70:peptide complexes in MHC class II-enriched compartments after receptor-
mediated endocytosis (208).  Interestingly, HSP70 has been shown to interact with MHC 
class II molecules (209).  Studies also suggest HSP70 mediated enhancement of MHC 
class II restricted peptide presentation (137, 209).  And relevant to autoimmunity, HSP70 
has been shown to promote myelin autoantigen presentation by MHC class II molecules 
(139).  Thus, a better understanding of the role of HSP70 in amyloidosis and 
autoimmunity may have implications on developing better therapeutics for these types of 
diseases.    
 
ER chaperones and MHC class II presentation 
The ER is a specialized environment where newly synthesized polypeptides are 
translocated, properly folded into functional proteins, and transported to their final 
destinations.  Nearly one third of all eukaryotic cellular proteins are translocated into the 
ER for processing (210).  Additional ER chaperones, folding enzymes, and resident 
proteins are also abundant in the ER at even higher levels than newly synthesized 
polypeptides.  Thus, the protein concentration in the ER lumen can be greater than 100 
mg/ml (211).    
 
Within the ER, there are quality control mechanisms that maintain homeostasis.  While 
properly folded proteins are exported from the ER, misfolded proteins are retained in the 
ER and selectively degraded.  Under some conditions, the cellular demand on ER 
 28 
protein-folding activities exceeds the ER’s capacity.  This situation of imbalance, termed 
ER stress, results in the accumulation of misfolded proteins and the triggering of 
intracellular signaling pathways called the unfolded protein response (UPR).  The UPR 
temporarily halts protein translocation, degrades the misfolded proteins, and induces ER 
chaperones and folding enzymes in order to increase ER folding and degradation capacity 
(212, 213).  If proteins cannot be folded correctly, they are targeted for removal from the 
folding pathway via the ER-associated degradation (ERAD).  Through ERAD, proteins 
are exported from the ER into the cytosol for proteasomal degradation.         
 
ER chaperones play critical roles within the ER under both homeostatic conditions and 
ER stress.  Two main ER chaperones, grp94 and BiP, are chaperones of the HSP families. 
Grp94 is an ER homolog of cytosolic HSP90 and is expressed at high levels within the 
ER.  The ER chaperone binding immunoglobulin protein (BiP or grp78) is a homolog of 
cytosolic HSP70 and is one of the most abundant ER chaperones.  Parallels are being 
drawn between the grp94/BiP chaperone complex in the ER and HSP90/HSP70 in the 
cytosol.  BiP functions in both protein folding and in ERAD.  Similar to HSP70, BiP 
recognizes hydrophobic regions that are exposed in misfolded or unassembled proteins 
and functions in an ATP-dependent manner.  However, additional research indicates that 
HSP90 may also be linked to the cellular transcriptional response to ER stress, suggesting 
that chaperones on both sides of the ER are involved in the ER stress response (214).     
 
Studies suggest that ER chaperones play critical roles in mammalian development and are 
linked to a wide variety of diseases.  ER chaperones are linked to the prevention of 
protein misfolding in neurodegenerative diseases, cancer progression and tumor 
immunity, atherosclerosis, type II diabetes, and autoimmune disease such as TID (215).  
In reference to autoimmune diseases, BiP has been shown to associate with autoantigens 
suggesting a possible mechanism for triggering autoimmunity (216).  Additional research 
has shown that in Ii deficient cells, MHC class II molecules can bind grp94 (217).  This 
suggests that in the absence of Ii, ER stress chaperones such as grp94 may bind to MHC 
class II molecules and retain them in the ER.  This process could prevent endogenous 
peptide loaded MHC class II molecules from exiting the ER and minimize the 
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autoimmune responses to endogenous self Ags.  Taken together, ER chaperones play 
critical roles in protein assembly and degradation under both normal and stressed 
conditions and may prove crucial to the maintenance of homeostasis in the immune 
system.   
  
Research summary 
As previously stated, studies suggest that HSPs such as HSC70 play important roles as 
chaperones in MHC class II presentation of exogenous and endogenous Ags.  I 
hypothesize that in addition to HSC70, both HSP90 and HSP70 can modulate MHC class 
II presentation of select Ags in B cells.  To determine if HSP90 is involved in MHC class 
II presentation, two pharmacological inhibitors of HSP90, GA and RA, were used to 
inhibit HSP90 chaperone activity.  The effect of HSP90 inhibition on MHC class II 
presentation of a variety of endogenous and exogenous Ags was measured.  Manipulation 
of HSP90 isoform expression was performed by using isoform specific siRNA.  The 
effect of inhibition of HSP90 isoform expression on MHC class II presentation of a 
variety of endogenous and exogenous Ags, including the autoantigen GAD, was 
measured.  Studies were performed to identify a possible mechanism for HSP90 
involvement in MHC class II presentation of select Ags.  A role for HSP70 in MHC class 
II presentation was also explored using additional endogenous and exogenous Ags.  
These studies should provide insights into the involvement of HSP90 and HSP70 in 
MHC class II presentation of select Ags such as GAD and may prove helpful in 
understanding the link between GAD, MHC class II, HSPs, and autoimmunity.  
 
This work also includes a study of a rare case of diabetes caused by type B insulin 
resistance due to development of insulin receptor autoantibodies during treatment for 
hepatitis C with interferon α and ribavirin.  Clinical and laboratory findings in the case 
are presented.  Literature on type B insulin resistance and interferon-induced 
autoimmunity is reviewed.  This case demonstrated that type B insulin resistance can 
occur as a complication of interferon α therapy.  This was the first case in the United 
States of type B insulin resistance with insulin receptor autoantibodies during treatment 
with interferon α.   
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MATERIALS AND METHODS 
Cell lines 
 The human B lymphoblastoid cell line (B-LCL) Priess is homozygous for HLA-DR4 
(DRA1*0101,DRB1*0401) expression.  Retroviral transduction of Priess cells with 
GAD65 cDNA resulted in constitutive endogenous expression of GAD65 yielding 
PriessGAD cells (67).  Another human B-LCL, Frev, expresses both the HLA-DR4 
(DRA*0101, DRB1*0401) and HLA-DR1 (DRA*0101, DRB1*0101) class II alleles.  
Transfection of Frev with a CMV promoter driven plasmid encoding SMA, a mutant 
form of immunoglobulin (Ig) light chain κ4, followed by drug selection with 500 µg/ml 
hygromycin resulted in constitutive endogenous expression of SMA yielding FrevSMA 
cells (207).  These B-LCL cells were maintained in Iscove’s MEM (Invitrogen, Grand 
Island, NY) supplemented with 10% heat-inactivated fetal calf serum (Hyclone, Logan, 
UT), 100 µ/mL penicillin, and 100 µg/mL streptomycin (Gibco BRL Life Technologies, 
Grand Island, NY).   
 
The T cell hybridoma 33.1 recognizes the GAD273-285 epitope within the context of HLA-
DR4 (L. Wicker, Merck Research Laboratories, Rahway, NJ).  The 1.21 T cell 
hybridoma recognizes the κII145-159 (kappa II) epitope of Ig κ within the context of HLA-
DR4 (P. Whitley, Merck). The T cell hybridoma 2.18 recognizes the κI188-203 (kappa I) 
epitope of Ig κ within the context of HLA-DR4 (P. Whitley, Merck).  The 17.9 T cell 
hybridoma recognizes the HSA64-76 epitope from human serum albumin (HSA) within the 
context of HLA-DR4 (Merck Research Laboratories, Rahway, NJ).  The HT-2 cell line is 
an IL-2 dependent T cell hybridoma (Merck Research Laboratories, Rahway, NJ). All T 
cell hybridomas were maintained in RPMI 1640 (Invitrogen, Grand Island, NY) 
supplemented with 10% fetal calf serum (Hyclone, Logan, UT), 50 µM β 
mercaptoethanol (βME) (Gibco BRL Life Technologies, Grand Island, NY), 100 µ /mL 
penicillin, and 100 µg/mL streptomycin.  For HT2 cells, an additional 20% T-Stim (BD 
Biosciences, Bedford, MA) was added to the T cell media. 
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CHO, Chinese hamster ovary cells, and CHO/IR cells (Jeffrey Pessin, University of Iowa, 
Iowa City, Iowa) were cultured in α MEM (Hyclone, Logan, UT)  with 10% heat-
inactivated calf serum. 
 
Antibodies 
The following antibodies were used in various immunoprecipitations, Western 
immunoblots, and flow cytometry assays in order to study HSP90 and HSP70 function in 
MHC class II presentation.  All of the following primary antibodies were to human 
proteins.  The rabbit anti-human kappa light chain pAb and the rabbit anti-GAD65 pAb 
were purchased from Sigma Aldrich (St. Louis, MO).  The mouse anti-GAPDH mAb was 
purchased from Chemicon (Temecula, CA).  The mouse anti-actin mAb, rabbit anti-
HSP90α pAb, rabbit anti-HSP90β pAb were all purchased from Neomarkers/Thermo 
Fisher (Fremont, CA).  The mouse anti-KDEL mAb, mouse anti-HSP90 mAb, rabbit 
anti-HSP40 pAb, mouse anti-HSP70 mAb, and rat anti-HSC70 mAb were all purchased 
from Assay Designs (Ann Arbor, MI).  The mouse anti-MHC class II DRα (DA6.147) 
and mouse anti-MHC class II dimers (L243) were provided by Peter Cresswell (Yale).  
The GAD6 Ab (mouse anti-GAD65) was obtained from the Developmental Studies 
Hybridoma Bank, Univ. Iowa (Iowa City, IA).  Various secondary antibodies were used 
in these studies. The goat anti-rabbit IgG-HRP Ab, goat anti-rat IgG-HRP Ab, and goat 
anti-mouse IgG-HRP Ab were all purchased from Jackson Laboratories (West Grove, 
PA).  The goat anti-mouse IgG-PE was purchased from Dako (Carpinteria, CA).  To 
detect ovalalbumin protein, specific rabbit anti-serum from Cappel Laboratoris was used 
(Downington, PA).  
 
For the co-immunoprecipitation assays performed in the case study of type B insulin 
resistance, the following antibodies were used.  The rabbit anti-insulin receptor α (N-20): 
sc-710 pAb and the rabbit anti-insulin receptor β (C-19): sc-711 pAb were purchased 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).  The goat anti-β actin pAb was 




Antigens, peptides, and proteins 
A variety of Ags, peptides, and proteins were used in the following study.  The human 
GAD65 Ag was provided by J. Elliott (University of Alberta) or purchased from Diamyd 
(Pittsburgh, PA).  The HSA Ag was purchased from Sigma Aldrich (St. Louis, MO).  The 
synthetic peptides GAD273-285 (IAFTSEHSHFSLK), kappa I 188-203 
(KHKVYACEVTHQGLSS), kappa II145-159 (KVQWKVDNALQSGNS), and HSA64-76 
(VKLVNEVTEFAKTK) were generated using FMOC technology, HPLC purified, and 
mass analyzed to confirm purity and structure.  Purified native, human HSP90 protein 
was purchased from Assay Designs (Ann Arbor, MI). Ovalbumin (OVA) protein was 
purchased from Sigma Aldrich (St. Louis, MO).  Kappa Ag isolated from human Bence 
Jones protein was purchased from Accurate Chemical and Scientific Corporation 
(Westbury, NY).    
 
Pharmacological inhibitors 
The HSP90 inhibitors, geldanamycin (GA) and radicicol (RA), were purchased from 
EMD (Rahway, NJ) and solubilized in DMSO.  GA was used at concentrations ranging 
from 0.09 to 1.8 µM, and RA was used at concentrations ranging from 1-5 µM.   
The lysosomal protease inhibitor leupeptin was solubilized in PBS and used at a 
concentration of 50 µM (Sigma Aldrich, St. Louis, MO). The toxicity of all inhibitors 
was tested to ensure a typical cell viability at > 85% following cell treatments. 
 
Amaxa siRNA nucleofection 
Target specific siRNA was used to specifically knockdown HSP90α and HSP90β 
expression.  HSP90α and HSP90β siRNA oligomers as well as RISC-free siRNA controls 
were produced by Dharmacon (Lafayette, CO).  As previously described, the target 
sequences for hsp90α knockdown were 5′-AAAGCGUUCAUGGAAGCUUUG-3′ and 
5′-AAGGCUGACUUGAUCAAUAAC-3′ while the siRNA specific for hsp90β was 5′-
AAGGCCAAGCACGACAAGTAC-3′. All oligonucleotides had 3′ dTdT overhangs 
(141).  HSP90α, HSP90β, and RISC-free control siRNA were used at concentrations 
between 20-200 pMol.  RISC-free siRNA lacks a signal for nuclear translocation and 
functions as a negative control siRNA for nucleofection.  Nucleofection of B cells with 
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siRNA and a GFP-expression plasmid was performed using the Lonza (Gaithersburg, 
MD) nucleofection kit V and program Y-01.  After nucleofection, B cells were incubated 
for 48 hours.     
 
Flow cytometry  
Flow cytometry was used to detect expression of MHC class II, CLIP, Ii, HLA-DM, and 
HLA-DO.  For cell surface expression, 5 x 10
5 
B cells were incubated with primary Ab 
for 60 min on ice, washed with ice cold phosphate buffered saline (PBS), and incubated 
with either FITC- or PE-conjugated F(ab’)2 fragments of goat anti-mouse IgG (1:200 
dilution) prior to aldehyde fixation.  For total expression, 5 x 10
5 
B cells were fixed in 1% 
paraformaldehyde (10 min, 25°C) and permeabilized with PBS + 1% bovine serum 
albumin (BSA) + 0.1% sodium azide (NaN3) + 0.1% saponin for 30 minutes on ice prior 
to Ab staining.  Flow cytometry was performed on a FACScan
TM
 and data analyzed using 
CELLQuest software.  
 
Antigen presentation assay 
To measure MHC class II presentation of endogenous Ags, treated B cells were washed 
in cold PBS, fixed in 0.5% paraformaldehyde (10 min, 25°C), and washed in cold B cell 
media to remove the paraformaldehyde.  For exogenous Ag or peptide presentation, B 
cells were pre-incubated with serially diluted Ags or peptides for 16 hours at 37°C prior 
to fixation.  Variable numbers of B cells (ranging from 1-5 x 10
4
 cells) were added to 
peptide specific T cells (1 x 10
4
) and incubated for 24 hours at 37°C.  The IL-2 dependent 
T cell line, HT2, was used to measure IL-2 production during the APC/T cell incubation.  
HT2 cells (5 x 10
3 
cells) were incubated with supernatants from the APC/T cell co-
cultures for 18 hours at 37°C.  [
3
H]-thymidine (2 µCi/well) was added to the HT-2 cells 
and incubated for another 8 hours at 37°C.  The cells were then harvested using a 96-well 
plate cell harvester (Skatron, Sterling, VA), and [
3
H] -thymidine incorporation was 
measured by liquid scintillation counting using a Wallac Microbeta plate reader 
(Gaithersburg, MD).  Data is expressed as the average counts per minute (CPM) of 




For co-immunoprecipitation assays with B cells, 1 x 10
7
 cells per sample were lysed in 
500 µl of either 1% Triton-X lysis buffer (10 mM Trizma base, 150 mM NaCl, 0.2 mM 
PMSF, 0.1 mM TLCK, 1% Triton-X 100, pH = 7.4) or 1% N-octyl-β-glucopyranoside 
lysis buffer (10 mM Trizma base, 150 mM NaCl, 0.2 mM PMSF, 0.1 mM TLCK 1% N-
octyl-β-glucopyranoside, pH = 7.4) for 15 minutes on ice.  Lysates were first centrifuged 
at 1000 RPM for 5 minutes, then re-centrifuged at 14,000 RPM for 10 minutes.  Pre-
clearing of the lysates was performed to remove any non-specific binding.  Normal rabbit 
serum (1:1,000 dilution) was added to the lysate and incubated at 4°C for 30 minutes 
while rocking.  Blocked, cold PBS-washed protein G sepharose beads (Sigma-Aldrich, 
St. Louis, MO) were added and incubated for an additional 15 minutes at 4°C while 
rocking.  The protein G sepharose beads were centrifuged at 7000 RPM at 4°C and the 
supernatant was collected.  Prior to use, protein G sepharose beads were blocked with a 
30 minute incubation at 4°C with rocking in TNNB buffer (50 mM Trizma base /HCL 
with pH= 8.0, 250 mM NaCl, 0.1% BSA, 0.02% NaN3, 0.2 mM PMSF, 0.1 mM TLCK), 
then washed and resuspended 1:1 with cold PBS.  Specific Abs or isotype control Abs 
were incubated with blocked, PBS-washed protein G sepharose beads overnight at 4°C 
while rocking.  After incubation, Ab-PGS complexes were washed with cold PBS and 
resuspended 1:1 with cold-PBS.  Pre-cleared cell lysates were added to the Ab-PGS 
complexes and incubated at 4°C for 18 hours while rocking.  The beads were then 
washed three times with lysis buffer without protease inhibitors.  Ag-Ab complexes were 
eluted with 50 µl 2X reducing sample buffer, boiled for 5 minutes, and briefly 
centrifuged.  Elutes were resolved on 10% SDS-PAGE and Western immunoblotting was 
performed as described below.   
 
For the co-immunoprecipitation assays CHO and CHO/IR cells were collected by 
scraping cells from plates with 10 mM Trizma Base, 150 mM NaCl, 0.2 mM PMSF, 0.1 
mM TLCK (pH = 7.4) buffer.  Cells were then homogenized with Daunce homogenizer 
and passed through a 20 gauge needle.  Following ultracentrifugation, cells were lysed in 
1% Triton-X 100, 10 mM Trizma Base, 150 mM NaCl, 0.2 mM PMSF, 0.1 mM TLCK 
(pH = 7.4).  Cell lysates were then pre-cleared, and co-immunoprecipitation was 
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performed. Cell lysates were pre-cleared with SACI.  Patient or control serum was added 
to cell lysates at 4°C overnight, followed by protein G sepharose for 1 hour at 4°C.  Ag-
Ab complexes were collected and washed prior to elution and analysis by 10% SDS-
PAGE and Western immunoblotting.   
 
Gel electrophoresis and Western immunoblotting 
 For cell lysates, 5 x 10
6 
cells were lysed in 250 ul of 1% Triton-X lysis buffer (10 mM 
Trizma Base, 150 mM NaCl, 0.2 mM PMSF, 0.1 mM TLCK, pH = 7.4) on ice for 15 
minutes.  Lysates were first centrifuged at 1000 RPM for 5 minutes, then re-centrifuged 
at 14,000 RPM for 10 minutes.  Cellular protein concentrations were determined by 
BioRAD protein assay (Hercules, CA).  Equal amounts of cell protein (50-100 µg) in 
either non-reducing or reducing sample buffer was resolved by either 10% or 12% SDS-
PAGE and transferred onto nitrocellulose membranes (BioRAD, Hercules, CA).  
Reducing sample buffer contained βME and was used in all cases except for the detection 
of invariant chain and MHC class II dimers.  Membranes were blocked in Blotto 
overnight at 4°C and incubated with specific antibodies.  HRP-conjugated secondary 
antibodies and enhanced chemiluminescence from Pierce (Rockford, IL) was used to 
visualize antibodies on membranes.  Densitometry was performed using the Quantity One 
program and electronic imaging (BioRAD, Hercules, CA).   
 
For analysis of additional proteins on the blots, the blots were stripped and reprobed with 
additional antibodies of interest.  Following development of the blot, any residual ECL 
was rinsed with TBS-T.  The blots were then stripped of bound antibodies by incubating 
the blots for 30 minutes at 65°C in a stripping solution containing 100 mM βME and 2% 
SDS. After washing to remove any residual stripping solution, the blots were blocked in 
Blotto and probed with additional antibodies.  This procedure could be repeated at least 3 
times with reproducible results.   
 
Media concentration for Western analysis 
Fresh and conditioned media was concentrated from 13 ml to approximately 50 µl using 
Centricon centrifugal filter devices with 50,000 and 30,000 NMWL Ultracel YM 
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membranes (Millipore, Billerica, MA).  Cultured cells were centrifuged at 1000 RPM for 
5 minutes to separate the cells from the media.  The supernatant was removed and 
centrifuged at 5000 x g max for 60 minutes in a Centricon filter device with 50,000 
NMWL membrane.  The concentrated media was removed and recentrifuged at 5000 x g 
for 30 minutes in a Centricon filter device with 30,000 NMWL membrane.   
 
Semi-quantitative RT-PCR 
Total RNA was extracted from treated B cells with an RNEasy Mini kit (Qiagen, 
Valencia, CA) following the manufacturer’s instructions. cDNA was generated from 
RNA using an Advantage RT for PCR kit from BD Biosciences.  Primers for PCR 
amplification were designed using the Custom Primers - OligoPerfect™ Designer 
software (Invitrogen, Grand Island, NY). The primers used for human Ii were 5'-GCT 
GTC GGG AAG ATC AGA AG-3'  (sense) and 5'-GCC ATA CTT GGT GGC ATT CT-
3' (antisense); for HLA-DRα 5'-CAA AGA AGG AGA CGG TCT GG-3' (sense) and 5'-
AGC ATC AAA CTC CCA GTG CT-3' (antisense); for human cathepsin S 5'-GGA TCA 
CCA CTG GCA TCT CT-3' (sense) and 5'-CCA GCT TTC CTG TTT TCA GC-3' 
(antisense); for human cathepsin B 5'-GCT ATC CTG CTG AAG CTT GG-3' (sense) and 
5'-CAT TGT CAC CCC AGT CAG TG-3' (antisense);  for human cathepsin D 5'-AGC 
TGG TGG ACC AGA ACA TC-3' (sense) and 5'-CTC TGG GGA CAG CTT GTA GC-
3' (antisense);  and for human cathepsin L 5'-TGT GGT TCT TGT TGG GCT TT-3' 
(sense) and 5'-CAG GCC TCC ATT ATC CTG AA-3' (antisense).  GAPDH primers 
were obtained from the Advantage RT for PCR kit. Amplification reactions were 
performed using 1.1×ReddyMix
TM
 PCR Master Mix (ABgene/Thermo Fisher, Rockford, 
IL) with different cycle times in a MJ Research thermal cycler. The number of 
amplification cycles for analysis was 20, 28, 30, 36, or 50 cycles.  The cycling  
parameters used were: 95°C, 15 sec; 50°C, 30 sec; and 68°C, 1 min. PCR products (10 
µl) were electrophoresed on 1% agarose gels, stained with SYBR
®
 safe DNA gel stain 
(Invitrogen, Grand Island, NY), and detected with UV transillumination using 
ChemiDoc
TM
 XRS (BioRad, Hercules, CA).  
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Cathepsin activity assays 
The following protocol for measuring cathepsin activity was adapted from the published 
protocol described by Kirschke and Wiedernanders (218).  For these assays, 5 ml glass 
tubes were used.  For each sample, 2 x 10
7
 cells were suspended in 0.5 ml of 20 mM 
Hepes, 0.5% Triton-X 100, pH = 6.5 with HCL and incubated for 3 minutes on ice.  Cells 
were homogenized with a Dounce homogenizer for 20 strokes on ice.  Homogenates were 
centrifuged at 1000 RPM for 5 minutes at 4°C.  Samples were serially diluted (1:2, 1:4, 
and 1:10) in diluent.  Buffer/Activator (50 µl) for each assay was added to the diluted 
samples and incubated for 2 minutes at room temperature.  50 µl of substrate solution 
was added and incubated for exactly 30 minutes for cathepsin B, 10 minutes for cathepsin 
S/L, and 60 minutes for cathepsin S assays.  After incubation, 200 µl of stopping buffer 
was added and mixed.  For each sample, 200 µl was transferred to a 96 well plate and 
analyzed for fluorescence with excitation at 360 nm and emission at 460 nm.  Samples 
were compared to a 0.5 µM 7-amino-4-methylcoumarin (AMC) standard.  The 
instrument was set to read 1000 arbitrary fluorescence units (FU) for the 0.5 µM AMC 
standard.  Cathepsin activity was calculated as the change in sample fluorescence units 
(FU) after 30 minutes.  Here, the observed FU for samples with protease at 30 minutes 
was corrected for background substrate hydrolysis by subtracting the FU of a control or 
blank sample lacking enzyme.   For cathepsins, international convention holds that 1 mU 
of enzyme activity can catalyze a change of 1000 FU per minute.  Thus, for a 30 minute 
assay, the following equation was used:  (X FU/30 minutes) x (1 min/1000 FU) = Y 
microunits of protease (µU).  The BioRad protein assay was performed to determine the 
total protein concentration of each sample.  Using the protein concentration, the total 
cathepsin activity per mg protein was calculated using the equation: (Y µU/ml lysate 
added)/ (mg/ml) protein concentration = X µU/mg. 
 
For all assays, the stop solution was 100 mM sodium monochloracetate (CH2ClCOONa), 
30 mM sodium acetate (NaCH3COO), 70 mM acetic acid (CH3COOH), pH = 4.3.  The 
10 mM AMC standard reconstituted in DMSO was diluted to a working concentration of 
0.1 µM with a 1:1 mixture of assay buffer:stopping reagent each day of use.  The diluent, 
buffer/activator, and substrates for each assay is listed as follows.  For cathepsin B, the 
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diluent was 0.1% Brij 35 detergent (Sigma), the buffer/activator was 352 mM 
monopotassium phosphate (KH2PO4), 48 mM disodium phosphate (Na2HPO4), 4 mM 
EDTA, pH = 6.0 with 8mM dithiothreitol (DTT) added on day of use, and the stock 
substrate solution was 1mM Z-Arg-Arg-AMC in DMSO, diluted to a working solution of 
20 uM in ddH20 on day of use.  For cathepsin S/L assays, the diluent was 0.1% Brij 35 
detergent (Sigma), the buffer/activator was 340 mM sodium acetate (NaCH3COO), 60 
mM acetic acid (CH3COOH), 4 mM EDTA, pH = 5.5 with 8mM DTT added on day of 
use, and the stock substrate solution was 1mM Z-Phe-Arg-AMC in DMSO, diluted to a 
working solution of 20 µM in ddH20 on day of use.  For cathespin S, the diluent was 
0.01% Triton-X-100, .1M potassium phosphate buffer, mM EDTA, pH=7.5; the 
buffer/activator was 0.1M potassium phosphate buffer/5mM disodium EDTA with 5mM 
DTT added on day of use; and the stock substrate solution was 10mM Z-Val-Val-Arg-
AMC in DMSO diluted to a working solution of 12.5 µM in ddH20 on day of use.   
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RESULTS 
Chapter 1.  HSP90 modulates GAD antigen presentation in B cells  
In order to study MHC class II presentation of GAD, two model B cell lines, Priess and 
PriessGAD, were utilized.  Both Priess and PriessGAD are EBV transformed human B 
cell lines homozygous for the diabetes susceptible MHC class II allele HLA-DR4.  
PriessGAD cells were generated by retroviral transduction of Priess with cDNA encoding 
the 65 kD form of human GAD (67).  Within the cytoplasm of cells, GAD is primarily 
associated with the outer face of vesicular organelles.  Previous studies from our lab 
showed that similarly in PriessGAD cells, GAD is also primarily associated with the 
cytoplasmic face of intracellular membranes (67).  Effective MHC class II presentation of 
the immunodominant T cell epitope GAD273-285 resulted from the expression of human 
GAD within the cytoplasm of PriessGAD cells (219).  Western immunoblotting of 
conditioned media from PriessGAD cells failed to detect any secreted GAD Ag 
suggesting that endogenous GAD is processed via an endogenous pathway (67).  When 
pulsed with exogenous human GAD Ag, Priess cells can present the immunodominant 
GAD273-285 epitope via MHC class II molecules (219).  Thus, the autoantigen GAD can 
be efficiently presented by MHC class II molecules either by cytoplasmic or extracellular 
(exogenous) routes.    
 
Pharmacological inhibition of HSP90 specifically decreases MHC class II 
Presentation of GAD 
HSP90 is constitutively expressed by all cells including islet beta cells and APCs.   In 
addition to cytoplasmic GAD, PriessGAD cells also express endogenous HSP90 at 
relatively high levels.  Previous studies in our laboratory implicated HSC70 as a player in 
MHC class II presentation of endogenous GAD.  HSC70 has been shown in the literature 
to interact with HSP90 (162).  Therefore, experiments were performed to determine 
whether HSP90, like HSC70, is involved in MHC class II presentation of GAD.  In order 
to explore the role of HSP90 in GAD Ag processing and presentation in B cells, we 
utilized two HSP90 inhibitors, GA and RA.  GA, a benzoquinone ansamycin antibiotic, 
and RA, a macrocyclic drug, have been shown to bind to HSP90 and inhibit its chaperone 
activity in cell lines and animals (177).  PriessGAD cells were treated for 18 hours with 
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increasing concentrations of GA and RA and analyzed for MHC class II presentation of 
endogenous, intracellular GAD.  Both GA and RA treatment of PriessGAD cells resulted 
in a dose-dependent decrease in MHC class II presentation of endogenous GAD (Fig. 8).  
Treatment of cells with GA and RA for 18 hours did not alter cell viability as assessed by 




Figure 8.  Pharmacological inhibition of HSP90 reduces MHC class II presentation 
of endogenous GAD Ag.  PriessGAD cells were treated with increasing 
concentrations of HSP90 inhibitors GA (A) or RA (B) for 18 hours prior to 
paraformaldehyde fixation.  MHC class II presentation of endogenous GAD was 
analyzed by T cell assays. Multiple control assays were carried out including 
analysis of the production of IL-2 by APCs or T cells cultured alone.  The 
negative control indicated here represents proliferation of HT-2 cells without 






Drug-treated PriessGAD cells were also analyzed for their capacity to present epitopes 
from another endogenous Ag, the kappa light chain of human Ig Ab.  The kappa light 
chain subunit is produced via the secretory pathway, transiting from the ER to the Golgi 
and routed to endosomes for secretion or to the cell surface via endosomes.  Previous 
studies in our lab using inhibitors of endo/lysosomal Ag processing suggest that kappa 
light chain is processed in acidic compartments.  Further studies have shown that epitopes 
of kappa light chain Ag are displayed by MHC class II molecules on the cell surface of 
Priess and PriessGAD cells.  PriessGAD cells were treated with increasing concentrations 
of GA or RA and analyzed for MHC class II presentation of both the dominant kappa I 
and sub-dominant kappa II epitopes from endogenous Ig kappa light chain.  GA or RA 
treatment did not alter MHC class II presentation of endogenous kappa I or kappa II 
epitopes (Fig. 9).  These results indicate that HSP90 inhibition by either GA or RA 
appears to perturb MHC class II presentation of select endogenous Ags such as GAD.  
These results point to a potential selectivity or specificity in HSP90 modulation of MHC 
class II presentation which may be linked to Ag or Ag localization.       
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Figure 9.  Pharmacological inhibition of HSP90 function does not affect MHC class 
II presentation of endogenous IgG kappa Ag.  PriessGAD cells were treated 
with increasing concentrations of HSP90 inhibitors GA (A and C) or RA (B and 
D) for 18 hours.  MHC class II presentation of two endogenous peptide epitopes 
encoded within the Ag IgG, termed kappa I (A and B) and kappa II (C and D) was 
analyzed by T cell assays. Control assays were carried out as in figure 8.  Here, 
the negative control indicates HT2 cell proliferation without IL-2 addition.   






The question remained whether HSP90 is involved in the classical exogenous MHC class 
II pathway or functions only in the endogenous MHC class II presentation pathway.  
Thus, Priess cells were treated with GA or RA and pulsed with several exogenous Ags 
and peptides prior to testing for MHC class II presentation.  Priess cells were first 
analyzed for the effect of GA and RA on MHC class II presentation of exogenous GAD 
Ag (Fig. 10A and B).  GA or RA treatment inhibited MHC class II presentation of 
exogenous GAD Ag by Priess cells.  To determine if the effect of GA and RA treatment 
was specific for Ag processing, GA or RA treated Priess cells were pulsed with the 
exogenous, synthetic GAD273-285 peptide and analyzed for MHC class II presentation of 
that specific epitope.  Neither GA nor RA affected MHC class II presentation of GAD 










Figure 10.  Pharmacological inhibition of HSP90 diminishes MHC class II 
presentation of exogenous GAD Ag, but not exogenous GAD peptide.  Priess 
cells were treated with either 0.18 µM GA (A and C) or 2 µM of RA (B and D) 
for 18 hours.  After 2 hours of drug treatment, exogenous GAD Ag (A and B) or 
GAD peptide (C and D) were added to these B cells for an additional 16 hours.  
MHC class II presentation of exogenous GAD (A and B) and exogenous GAD 
peptide (C and D) by B cells prior to paraformaldehyde fixation and T cell assays. 
Control assays were carried out as in Figure 8.  Here, the negative control is 
GA/RA treated Priess cells without exogenous Ag/peptide added.  Results are 
representative of at least 3 separate experiments. 
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To further address the Ag specificity of GA and RA treatment on MHC class II 
presentation in B cells, the effect of drug treatment on the presentation of an epitope from 
human serum albumin (HSA) Ag was examined.  PriessGAD cells pulsed with whole 
HSA Ag can present HSA epitopes including the HSA64-76 epitope via MHC class 
molecules.  GA and RA treated PriessGAD cells were pulsed with exogenous HSA Ag 
and measured for MHC class II presentation of this HSA epitope.  Neither GA nor RA 
treatment of PriessGAD cells affected MHC class II presentation of HSA64-76 epitope 
from exogenous HSA Ag (Fig. 11A and B).  GA or RA treated PriessGAD cells were 
also pulsed with the exogenous, synthetic HSA64-76 peptide and analyzed for MHC class 
II presentation of this epitope.  MHC class II presentation of the exogenous HSA64-76 
peptide was not affected by GA or RA treatment.  Taken together, these results suggest 
that disruption of HSP90 function by GA and RA selectively inhibits MHC class II 
presentation of GAD epitopes derived from both exogenous and endogenous sources of 
GAD Ag.   
 46 
 
Figure 11.  Pharmacological inhibition of HSP90 function does not affect MHC class 
II presentation of exogenous HSA Ag or exogenous HSA peptide.  PriessGAD 
cells were treated with either 0.18 µM GA (A and C) or 1 µM of RA (B and D) 
for 18 hours.  After 2 hours of drug treatment, exogenous HSA Ag (A and B) or 
HSA peptide (C and D) were added to PriessGAD B cells.  MHC class II 
presentation of exogenous HSA (A and B) and exogenous HSA peptide (C and D) 
by these B cells was analyzed by T cell assays.  Control assays were carried out as 
in Figure 9.  Here, the negative control is GA/RA treated Priess cells without 
exogenous Ag/peptide added. Results are representative of at least 3 separate 
experiments.  
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Pharmacological inhibition of HSP90 induces a stress response in B cells 
Prolonged exposure of cells to HSP90 inhibitors can induce a stress response, as 
monitored by increased cellular expression of HSP70, HSP90, HSC70, and HSP40 
protein levels (179, 220, 221).  To determine if RA and GA were inducing a stress 
response in B cells, levels of intracellular HSP90, HSP70, HSC70, and HSP40 protein 
were measured by Western immunoblotting.  Results show that both RA and GA 
treatments significantly induce HSP70 expression and to a lesser extent HSP40 (Fig. 12).   
HSP90 expression is also slightly induced by RA treatment as cells attempt to 
compensate for loss of HSP90 function as previously reported (Fig. 12) (179, 220, 221).    
However, statistical analysis determined this induction was not statistically significant.  
These results indicate that inhibition of HSP90 function by RA and GA treatment induces 




Figure 12.  Pharmacological inhibition of HSP90 induces a stress response. 
PriessGAD cells were treated with either RA, GA, or DMSO as a control for 18 
hours.  (A)  Whole cell lysates from treated cells were fractionated on 10% SDS-
PAGE gel and Western immunoblotted for HSP90, HSC70, HSP70, HSP40, and 
actin protein expression.  (B)  Densitometry of the representative experiment in 
panel A.  Results are representative of at least 2 separate experiments.  (C)  The 
average relative expression of HSP/HSC +/- SEM as determined by analysis of at 
least 2 separate experiments.  *Statistically significant as determined by student t 
tests.   
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Studies have shown that cell stress such as heat shock can promote enhanced Ag 
processing and MHC class II presentation of some exogenous and endogenous Ags by B 
cells (222).  It is possible that the altered Ag presentation seen in drug treated PriessGAD 
cells was due to their induction of a stress response rather than HSP90 inhibition. 
Experiments were performed to determine if cell stress by heat shock altered GAD Ag 
presentation. PriessGAD cells were heat shocked to mimic the stress response that was 
observed upon RA/GA treatment.  PriessGAD cells were incubated at 37, 40, or 42°C for 
20 minutes followed by a 24 hour incubation at 37°C.  Exposure of PriessGAD cells to 
40 or 42°C resulted in significantly increased HSP90, HSP70, and HSP40 expression 
confirming an induced stress response (Fig. 13).  Previous studies in the lab have shown 
that this increase in HSP/HSC expression was maintained for up to 48 hours (data not 
shown).  To determine the effect of this stress on Ag presentation, heat stressed 
PriessGAD cells were assayed for endogenous GAD, exogenous HSA Ag, and HSA 
peptide presentation.  Heat stressing PriessGAD cells did not alter MHC class II 
presentation of endogenous GAD, exogenous HSA Ag, or exogenous HSA peptide 
(Fig.14).  These results indicate that while RA and GA each induced a stress response 
and upregulated overall HSP/HSC expression in B cells, cellular stress alone does not 
contribute to the observed decrease in MHC class II presentation of GAD Ag associated 




Figure 13.  Heat stress induces HSP expression in B cells.  PriessGAD cells were 
incubated for 20 minutes at 37, 40, or 42°C in medium plus 10% heat inactivated 
serum followed by a 24 hour incubation at 37°C.  (A)  Whole cell lysates were 
fractionated on 10% SDS-PAGE gels and Western immunoblotted for HSP90, 
HSC70, HSP70, HSP40, and actin protein expression.  Blot is representative of at 
least 2 separate experiments.  (B) Average relative expression of HSP/HSC +/- 
SEM as determined by densitometry from at least 2 separate experiments is 




Figure 14.  Heat stress does not alter MHC class II presentation of endogenous GAD 
Ag, endogenous IgG kappa Ag, exogenous HSA Ag, or exogenous HSA 
peptide.  PriessGAD cells were incubated for 20 min at  37, 40, or 42 °C 
followed by a 24 hr incubation at 37°C with either 5 µM of exogenous HSA Ag 
(C) or exogenous HSA peptide (D) added after 8 hours.  Samples of B cells were 
divided and assayed by T cell assay for MHC class II presentation of endogenous 
GAD epitope (A), endogenous kappa II epitope (B), or HSA epitopes from 
exogenous HSA Ag (B) or HSA peptide (C).  Control assays were carried out as 
in Figure 8.  Here, the negative control indicates HT2 cell proliferation without 
IL-2 addition. Results are representative of at least 3 separate experiments.  
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Pharmacological inhibition of HSP90 does not alter MHC class II expression 
In a study using macrophages, HSP90 overexpression was found to enhance MHC class 
II dimer stability while GA and RA treatments decreased dimer stability (142).  Both 
HSP90 overexpression and inhibition were reported not to alter surface and total MHC 
class II protein expression in these murine cells (142).  To evaluate whether GA or RA 
inhibition of HSP90 altered MHC class II expression levels in human B cells, PriessGAD 
cells were treated with either agent, and then evaluated for total cellular MHC class II 
mRNA and protein expression as well as MHC class II surface expression.  To determine 
if HSP90 inhibition affects MHC class II transcription, RT-PCR was performed on RA, 
GA, or control treated cells.  HSP90 inhibition by RA or GA did not alter MHC class II 
RNA expression levels (Fig. 15A).  Western immunoblotting was performed on RA, GA, 
or control treated cells to measure the total cellular content of MHC class II DRα 
monomers or dimers.  Neither GA nor RA significantly altered the total cellular content 
of MHC class II DRα monomers as detected by Western immunoblotting (Fig. 15B).  
While MHC class II monomer expression was not affected, dimerization of MHC class II 
α and β chains could be altered.  Therefore, the effect of RA and GA on MHC class II 
dimerization in B cells was explored.  Western immunoblotting for MHC class II dimers 
showed that steady state levels of MHC class II dimers were also unchanged by GA or 






Figure 15.  Pharmacological inhibition of HSP90 does not alter MHC class II mRNA 
or protein expression.  PriessGAD cells were treated with DMSO as a control, 
RA (2 µM), or GA (0.18 µM) for 18 hours.  (A) Following treatment, mRNA was 
prepared and transcribed to cDNA.  From each sample, cDNA was subjected to 
PCR to amplify sequences from MHC II α chain and GAPDH.  PCR products 
were resolved on an agarose gel with SyberSafe stain. Results shown are 
representative of at least 2 separate experiments.  (B) Whole cell lysates from 
treated cells were analyzed by Western immunoblotting for expression of MHC 
class II DRα chain (left) or MHC class II DR αβ dimers (right).  Results shown 
are representative of at least 3 separate experiments. (C) The table depicts the 
average relative expression of MHC class II DRα and Dr αβ dimers +/- SEM.  
Student t tests determined no significant change in MHC class II expression.      
 54 
Additionally, flow cytometry of RA and GA treated cells was used to examine total 
cellular levels of MHC class II dimers.  This analysis confirmed no alteration of total 
MHC class II dimer expression (Fig 16A).  The observed decreases in MHC class II 
GAD Ag presentation could result from decreased surface expression of MHC class II 
dimers, even though total monomer and dimer expression remained stable.  Therefore, 
surface levels of MHC class II dimers were also examined by flow cytometry.  Analysis 
indicated that GA and RA did not decrease surface MHC class II dimer expression (Fig. 
16B).  Taken together, these results indicate that the decrease in MHC class II GAD Ag 
presentation observed with GA or RA treatment is not due to alterations in MHC class II 
expression or dimer stability in B cells. 
 
 
Figure 16.  Pharmacological inhibition of HSP90 does not alter total or surface 
MHC class II expression  PriessGAD cells were treated with DMSO as a 
control, RA (2 µM), or GA (0.18 µM) for 18 hours.  (A)  Following treatment, 
cells were fixed in 1% paraformaldehyde, permeabilized, and stained for total 
MHC class II expression or isotype control (Iso).  (B)  For surface MHC class II 
expression, cells were first stained for surface MHC class II expression or isotype 
control (Iso) and then fixed in 1% paraformaldehyde.  MHC class II expression 
was detected by flow analysis.  Thick black line indicates control cells, thin gray 
line indicates GA treated cells, dashed black line indicates RA treated cells, and 
thin gray line indicates isotype control staining.  Results shown are representative 
of at least 3 separate experiments.  
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HSP90 selectively associates with GAD Ag 
HSP90 can bind to both proteins and peptides to potentiate intra- and extracellular 
transport, folding, and proteolysis.  HSP90 has been shown to bind peptides for both 
direct and indirect MHC class I presentation (223).  While results thus far suggest HSP90 
is involved in MHC class II presentation of GAD Ag, it is unknown whether HSP90 
interacts with native GAD Ag.  Thus, experiments were performed to determine whether 
HSP90 naturally associates with cytoplasmic GAD Ag using the human B cell line 
PriessGAD.  Using lysates from PriessGAD cells, immunoprecipitations were performed 
with either GAD specific or IgG isotype control Abs.  Following SDS-PAGE and transfer 
onto nitrocellulose, blots were probed with an HSP90 specific antibody.  The results 
show that GAD co-immunoprecipitated with HSP90, while an IgG isotype control Ab 
failed to immunoprecipitate HSP90 confirming specificity (Fig.17A).  These results 
demonstrate intracellular association of HSP90 and GAD in cells co-expressing these 
proteins.  Our results suggest that HSP90 inhibition does not affect MHC class II 
presentation of endogenous Ig kappa.  One explanation for this result is that unlike GAD 
Ag, Ig kappa Ag may not be a client protein for HSP90.  Co-immunoprecipitation 
experiments were performed on PriessGAD whole cell lysates to determine if Ig kappa 
Ag associates with HSP90 in PriessGAD cells co-expressing these proteins.  Unlike GAD 
Ag, Ig kappa Ag was not found associated with HSP90 (Fig. 17A).   
 
Intracellularly, HSP90 has been shown to work in concert with other HSPs including 
HSC70, HSP70, and HSP40 (162, 167).  The association of HSP90 with GAD could be 
due to a direct interaction of these two molecules or an indirect interaction via binding 
through an additional HSP.  In order to determine if HSP90 and GAD can directly 
interact, purified HSP90 protein was incubated with purified GAD Ag followed by 
immunoprecipitation with GAD, HSP90, or IgG isotype control Abs.   
Immunoprecipitates were Western immunoblotted with GAD and HSP90 Abs.  HSP90 
was detected co-precipitating with GAD, indicating that HSP90 can bind directly to GAD 
(Fig. 17B).  As a control, HSP90 was also incubated with purified Ig kappa light chain 
and immunoprecipitated with HSP90, Ig kappa light chain, or IgG isotype control Abs.  
Western immunoblotting did not detect Ig kappa light chain associated with HSP90 
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confirming that the interaction between HSP90 and GAD is not due to nonspecific 
binding.  These results suggest the association of HSP90 and GAD seen in PriessGAD 
lysates is likely due to a direct association of these two proteins.  HSP90 inhibition by 
GA was found to decrease MHC class II presentation of exogenous OVA (ovalbumin) 
Ag in APCs (142).  The authors suggested that the effect of HSP90 inhibition on OVA 
Ag presentation was due to alterations in overall MHC class II expression.  However, 
another possible explanation could be that HSP90 may bind to OVA Ag and selectively 
chaperone OVA Ag for MHC class II presentation.  To determine if HSP90 could 
directly interact with OVA Ag, purified HSP90 was pre-incubated with purified OVA Ag 
and immunoprecipitated with HSP90, OVA, or IgG isotype control Abs.  HSP90 was 
found to co-immunoprecipitate with OVA Ag, indicating that HSP90 and OVA Ag can 
directly interact in vitro (Fig. 17B).  These results suggest that the previously published 
results could be due to selective chaperone activity of HSP90 and not due to overall 




Figure 17.  HSP90 selectively associates with GAD Ag.  (A and B)  PriessGAD whole 
cell lysates were incubated overnight at 4°C with anti-GAD Ab, anti-HSP90 Ab, 
anti-kappa light chain, or the isotype control IgG Ab bound to protein-G 
sepharose beads.  Immunoprecipitated proteins eluted with 2X reducing sample 
buffer were subjected to 10% SDS-PAGE and Western immunoblotting with anti-
HSP90 Ab.  Whole cell lysate (WCL) was run as a positive control.  (B)  Purified 
GAD, kappa light chain, or OVA protein was pre-incubated with HSP90 at a 3:1 
molar ratio overnight at 37°C prior to immunoprecipitation with anti-HSP90 Ab, 
anti-GAD Ab, anti-kappa light chain, anti-OVA Ab, or isotype control IgG Ab 
bound to protein-G sepharose beads.  Immunoprecipitated proteins eluted with 2X 
reducing sample buffer were subjected to 10% SDS-PAGE and Western 
immunoblotting with anti-HSP90 Ab.  WCL was run as a control for 
immunoblotting.  Gamma settings were adjusted in panel B.  Results are 
representative of at least 3 separate experiments.   
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HSP90α and HSP90β isoform expression is altered with isoform specific siRNA 
In humans, HSP90 is constitutively expressed as two closely related isoforms, HSP90α 
and HSP90β (170).  Assays using pharmacological inhibitors such as RA and GA fail to 
distinguish between the function of these two isoforms, with both proteins inactivated by 
these compounds (174).  While both isoforms bind similarly to their intracellular co-
chaperones, in some cases HSP90α and HSP90β were found to behave differently with 
respect to substrate interactions (178).  Research has implicated HSP90α, but not HSP90β 
in regulating class I presentation (141).  However, a role for HSP0α and HSP90β isoform 
in MHC class II presentation in B cells has yet to be explored.  To investigate the 
function of HSP90 isoforms in MHC class II presentation of GAD Ag in B cells, a panel 
of B cells was examined for steady state HSP90α and HSP90β expression.  Equal 
amounts of protein from Priess, PriessGAD, Frev, and FrevSMA whole cell lysates were 
Western immunoblotted with HSP90α and HSP90β specific antibodies.  Both HSP90α 
and HSP90β isoforms were detected in Priess, PriessGAD, Frev, and FrevSMA (Fig. 18).  
Moreover, HSP90α and HSP90β isoforms appear to be expressed at measurable levels at 
steady state conditions in all B cells tested.  
 
 
Figure 18.  HSP90α and HSP90β are abundantly expressed in B cells.  Equal amounts 
of  protein from Priess (P), PriessGAD (PG),  Frev (F), and FrevSMA (FS) whole 
cell lysates were fractionated by 10% SDS-PAGE and Western immunoblotted 
with either HSP90α or HSP90β specific Abs.          
 
To further evaluate the biological function of these HSP90 isoforms in MHC class II 
presentation, siRNA specifically designed to disrupt HSP90α and HSP90β mRNA 
expression were utilized (141).  PriessGAD cells were nucleofected with HSP90α or 
HSP90β siRNA as well as controls such as a RISC-free siRNA.  Co-nucleofection with a 
GFP-containing plasmid was performed as a nucleofection control.  Flow cytometry of 
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nucleofected cells to detect GFP positive cells indicated that DNA transfection efficiency 
ranged from 45-55% of cells.  Total protein expression of HSP90α, HSP90β, actin, and 
GAPDH was determined by Western immunoblotting.  Treatment of B cells with 
HSP90α siRNA specifically knocked down HSP90α expression, but did not affect 
HSP90β levels (Fig. 19).  Densitometry indicated that HSP90α siRNA treatment resulted 
in a 66% decease in HSP90α protein expression compared to either HSP90β or control 
siRNA treated cells.  HSP90β siRNA treatment of B cells decreased HSP90β protein 
expression, but did not consistently affect HSP90α protein abundance (Fig. 19).  HSP90β 
protein expression was decreased to 60% when compared to HSP90α siRNA treated or 
control siRNA treated cells.   
 
 
Figure 19.  HSP90 isotype specific siRNA specifically inhibits HSP90α and HSP90β 
expression.   PriessGAD cells were nucleofected with siRNA for HSP90α, 
HSP90β, or controls such as RISC-free siRNA as well as the plasmid pMaxGFP 
and incubated for 48 hr at 37˚C.  Flow cytometry of nucleofected cells to detect 
GFP-positive cells indicated the DNA transfection efficiency ranged from 45-
55% cells.  (A)  Whole cell lysates were analyzed for HSP90α, actin, HSP90β, 
and GAPDH expression by Western immunoblotting.  (B)  Densitometry 
confirmed specific disruption of each HSP90 isoform expression by its respective 
siRNA. Results are representative of at least 3 separate experiments.  
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In contrast to HSP90 inhibition by RA and GA, neither HSP90α nor HSP90β siRNA 
treatment altered HSP70, HSC70, or HSP40 protein expression levels in cells (Fig. 20).  
This may be due to low levels of residual HSP90α or HSP90β in siRNA treated cells.   
 
 
Figure 20. Inhibition of HSP90α or HSP90β by siRNA does not induce a heat stress 
response. PriessGAD cells were treated with HSP90α, HSP90β, or control siRNA 
and incubated for 48 hours as previously described.  (A) Whole cell lysates from 
treated cells were fractionated on 10% SDS-PAGE gel and Western 
immunoblotted for HSC70, HSP70, HSP40, and GAPDH. (B) Densitometry of 
the representative experiment.  Results are representative of at least 3 separate 
experiments.  
 
Total cellular MHC class II monomer and dimer protein abundance were unaffected by 
siRNA treatment as confirmed by Western immunoblotting (Fig. 21A).  Flow cytometry 
of permeabilized and non permeabilized cells indicated no affect of these siRNAs on 
MHC class II expression (Fig. 21C).  Together, these results suggest that HSP90α or 
HSP90β siRNA treatment specifically knocks down the expression of discrete HSP90 
isoforms, respectively, without altering the expression of MHC class II and other HSPs.   
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Figure 21.  Inhibition of HSP90α or HSP90β by siRNA does not alter MHC class II 
expression.  PriessGAD cells were treated with HSP90α, HSP90β, or control 
siRNA and incubated for 48 hours as previously described.  (A)  WCLs of treated 
cells were analyzed by Western immunoblotting for MHC class II α chain (left) 
and MHC class II dimers (right).  Results are representative of at least 2 separate 
experiments.  (B)  The table depicts the average relative expression of MHC class 
II α and αβ dimers +/- SEM as determined by densitometry of at least 2 separate 
experiments.  (C)  PriessGAD cells treated with siRNA were fixed in 1% 
paraformaldehyde, permeabilized, and stained for total MHC II dimers by flow 
cytometry.  Thick black line indicates control siRNA treated cells, thin black line 
indicates HSP90α siRNA treated cells, hashed black line indicates HSP90β 
siRNA treated cells, and thin gray line indicates isotype control staining (Iso).  
Results are representative of at least 2 separate experiments.   
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Disruption of HSP90α or HSP90β specifically inhibits MHC class II presentation of 
GAD   
To determine the role of HSP90α and HSP90β in MHC class II presentation, PriessGAD 
cells were treated with siRNA for HSP90α, HSP90β, or controls such as RISC-free 
siRNA followed by analysis of MHC class II presentation for several Ags and epitopes. 
Treatment of PriessGAD cells with either HSP90α or HSP90β siRNA resulted in 
decreased MHC class II presentation of endogenous GAD (Fig. 22).  
 
Figure 22.  HSP90α and HSP90β siRNA inhibits MHC class II presentation of 
endogenous GAD Ag.  PriessGAD cells were treated with either HSP90α (A), 
HSP90β (B), or control siRNA (A and B) and incubated for 48 hours as 
previously described.  Following siRNA treatment of B cells, MHC class II 
presentation of endogenous GAD was measured by T cell assays.  In each panel, 
black bars represent control cells, dotted bars represent HSP90α siRNA-treated 
cells, and hashed bars represent HSP90β siRNA-treated cells.  Control assays 
were carried out as in Figure 8.  Results are displayed as proliferation above 
background.  Results are representative of at least 3 separate experiments.   
 
Neither HSP90α nor HSP90β siRNA affected MHC class II presentation of endogenous 
kappa I or kappa II epitopes from endogenous IgG kappa light chain (Fig. 23). These 
results indicate that individual inhibition of HSP90α and HSP90β isoform expression by 
isoform specific siRNA perturbs MHC class II presentation of select endogenous Ags 
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such as GAD.  These results point to a potential selectivity or specificity for HSP90α and 
HSP90β modulation of MHC class II presentation which is linked to Ag.   
 
Figure 23.  HSP90α and HSP90β siRNA does not alter MHC class II presentation of 
endogenous kappa epitopes.  PriessGAD cells were treated with either HSP90α, 
HSP90β, or control siRNA and incubated for 48 hours as previously described.  
Following siRNA treatment of B cells, MHC class II presentation of endogenous 
kappa I or kappa II epitopes was measured by T cell assays.  In each panel, black 
bars represent control cells, dotted bars represent HSP90α siRNA-treated cells, 
and hashed bars represent HSP90β siRNA-treated cells. Control assays were 
carried out as in Figure 8. Results are displayed as proliferation above 
background. Results are representative of at least 3 separate experiments.   
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Pharmacological inhibition of HSP90 indicated that HSP90 modulates MHC class II 
presentation of a select GAD epitope from exogenous GAD Ag, but not exogenous GAD 
peptide.  To determine which HSP90 isoform is involved HSP90α or HSP90β siRNA 
treated cells were pulsed with either exogenous GAD Ag or synthetic GAD peptide and 
analyzed for MHC class II presentation of GAD epitope.  HSP90α or HSP90β siRNA 
treatment decreased MHC class II presentation of GAD epitope from exogenous GAD 










Figure 24.  HSP90α and HSP90β siRNA inhibits exogenous GAD Ag but not GAD 
peptide presentation. Priess cells were treated with either HSP90α, HSP90β, or 
control siRNA and incubated for 48 hours as previously described.  At 32 hours 
post nucleofection, 10 µg/ml exogenous GAD Ag (A and B) or 2 µM GAD 
peptide (C and D) was added to cells and incubated an additional 16 hours.  At 48 
hours post siRNA treatment of these cells, MHC class II presentation of GAD 
epitopes from either exogenous GAD Ag or GAD peptide was measured by T cell 
assays.  In each panel, black bars represent control cells, dotted bars represent 
HSP90α siRNA-treated cells, and hashed bars represent HSP90β siRNA-treated 
cells. Control assays were carried out as in Figure 8. Results are displayed as 
proliferation above background. Results are representative of at least 3 separate 
experiments. 
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HSP90α or HSP90β siRNA treated cells were also pulsed with either HSA protein or 
HSA peptide and assayed for MHC class II presentation of an HSA epitope.  HSP90α or 
HSP90β siRNA treatment did not alter MHC class II presentation of the HSA epitope 
using either exogenous HSA Ag or HSA peptide as a source of this epitope (Fig. 25).  
Taken together, these results indicate that both HSP90α and HSP90β isoforms can 
regulate MHC class II presentation of GAD Ag.  Thus, these studies establish that in 
contrast to MHC class I Ag presentation, both HSP90α and HSP90β can regulate the 
MHC class II pathway.  Furthermore, HSP90 appears to selectively promote MHC class 




Figure 25.  HSP90α and HSP90β siRNA does not affect MHC class II presentation 
of exogenous HSA Ag or exogenous HSA peptide.  PriessGAD cells were 
treated with either HSP90α, HSP90β, or control siRNA and incubated for 48 
hours as previously described.  At 32 hours post siRNA treatment, exogenous 
HSA Ag (5 µM) or HSA peptide (5 µM) was added to nucleofected cells and 
incubated an additional 16 hours.  At 48 hours post siRNA treatment of cells, 
MHC class II presentation of HSA epitopes from either exogenous HSA Ag or 
HSA peptide was measured by T cell assays.  In each panel, black bars represent 
control cells, dotted bars represent HSP90α siRNA-treated cells, and hashed bars 
represent HSP90β siRNA-treated cells. Control assays were carried out as in 
Figure 8.  Results are representative of at least 3 separate experiments.  
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Chapter 2.  Mechanistic analysis of HSP90 regulation of GAD Ag presentation in B 
cells 
HSP90α and HSP90β appear to regulate both endogenous and exogenous presentation of 
GAD Ag.  Analysis of MHC class II presentation of short synthetic GAD epitopes failed 
to reveal a role for HSP90 in the cell surface loading of MHC class II molecules or T cell 
recognition.  Thus, HSP90 may exert its effect on intracellular GAD Ag processing or 
MHC class II binding of GAD epitopes.  The pathways of exogenous and endogenous 
MHC class II presentation of GAD Ag are distinct yet converge with shared processing 
of GAD in endosomal and lysosomal compartments.  Studies from our lab and others 
showed endogenous Ag processing for MHC class II presentation to be dependent upon 
cytoplasmic proteases including the proteasome and calpain; exogenous Ag processing 
was not affected by inhibition of the proteasome or calpain (67, 69).   Further evidence 
has implicated HSC70 and lamp2a as chaperones of endogenous GAD presentation by 
MHC class II molecules (85).  Additional studies in our lab have shown that exogenous 
GAD Ag is processed via the classical MHC class II presentation pathway requiring 
endo/lysosomal acidification as well as cysteine and aspartyl proteases within those 
vesicles (67).     
 
However distinct, the two pathways of MHC class II presentation share some 
characteristics.  While endogenous GAD is processed in the cytoplasm by cytosolic 
proteases into peptide fragments, those peptides must be translocated into membrane 
organelles for MHC class II presentation.  Once translocated into those vesicles, further 
trimming of the GAD peptides is mediated by acidic proteases within endo/lysosomes 
(67).  Taken together, these studies indicate some overlap between the classical MHC 
class II presentation pathway for exogenous GAD and the alternative MHC class II 
presentation of endogenous GAD.  With evidence for a role for HSP90 in both of these 
pathways, further studies were carried out to determine whether HSP90 is affecting a 





Inhibition of HSP90 and invariant chain processing 
During transit through the Golgi secretory network, MHC class II molecules are 
chaperoned by Ii.  Ii functions as a chaperone to stabilize MHC class II dimers, target 
them to secretory vesicles, and prevent premature peptide loading.  As shown 
schematically in Figure 5, while progressing through the endosomal/lysosomal network, 
Ii undergoes stepwise degradation by lysosomal proteases to the smaller peptide 
fragments LIP and SLIP and the final fragment called CLIP, which remains associated 
with the MHC class II peptide binding groove.  Ii is proteolytically cleaved by lysosomal 
proteases during transit (31, 40-44, 47).  Studies have shown that alterations in Ii 
processing result in altered MHC class II presentation (79, 81, 90-93).  Therefore, 
disruption of Ii or its chaperone function could be a possible explanation for decreased 
GAD presentation by HSP90 inhibition.   
 
To determine if HSP90 inhibition affects Ii processing, PriessGAD cells were treated 
with RA (2 µM), GA (0.18 µM), or DMSO solvent as a control for 18 hours and analyzed 
for Ii mRNA expression by semi-quantitative RT-PCR.  Neither RA nor GA altered Ii 
mRNA expression in PriessGAD cells (Fig 26).   
 
Figure 26.  Pharmacological inhibition of HSP90 does not alter Ii mRNA levels.  
PriessGAD cells were treated with either DMSO control, RA (2 µM), or GA (0.18 
µM) for 18 hours.  Following treatment, mRNA was isolated from cells and 
reverse transcribed to cDNA samples were subjected to PCR to amplify Invariant 
Chain (Ii) and GAPDH sequences using multiple cycles of amplification.  In this 
figure, 30 cycles was used to amplify Ii and GAPDH sequences.  PCR products 
were resolved on an agarose gel with SyberSafe stain.  Results are representative 




Control, RA, and GA treated cells were also analyzed for total Ii expression by flow 
cytometry.  Neither RA nor GA affected total Ii expression in PriessGAD cells (Fig. 
27A).  To further determine if HSP90 inhibition could affect Ii processing, PriessGAD 
cells were treated with HSP90α, HSP90β, and control siRNA and analyzed for total Ii 
expression by flow cytometry.  Neither inhibition of HSP90α or HSP90β isoforms altered 
total Ii expression in PriessGAD cells (Fig. 27B).   
 
Figure 27.  Inhibition of HSP90α and HSP90β does not alter total cellular Ii 
expression.  (A)  PriessGAD cells were treated with DMSO as a control, RA (2 
µM), or GA (0.18 µM) for 18 hours.  (B)  PriessGAD cells were treated with 
HSP90α, HSP90β, or control siRNA as previously described and incubated for 48 
hours.  Following treatment, cells were fixed in 1% paraformaldehyde, 
permeabilized, and stained for total Ii expression using Abs and flow cytometry.  
(A) Black line indicates control cells, dark gray line indicates RA treated cells, 
light gray line indicates GA treated cells, and thin gray line indicates isotype 
control.  (B) Thick black line indicates siRNA control treated cells, thin black line 
indicates HSP90α siRNA treated cells, hashed black line indicates HSP90β 
siRNA treated cells, and thin gray line indicates isotype control staining.  Results 
shown are representative of at least 2 separate experiments.  
 
To determine if HSP90α and HSP90β inhibition influences Ii cleavage to CLIP, drug or 
siRNA treated PriessGAD cells were analyzed for total and surface CLIP expression by 
flow cytometry.  Total and surface CLIP expression in PriessGAD cells was not affected 
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by RA or GA treatment (Fig. 28A and B).  Additionally, neither HSP90α or HSP90β 
siRNA treatment altered total CLIP expression in PriessGAD cells (Fig. 28C).  
 
Figure 28.  Inhibition of HSP90α and HSP90β does not alter total or surface CLIP 
expression. (A and B) PriessGAD cells were treated with DMSO as a control, RA 
(2 µM), or GA (0.18 µM) for 18 hours.  (C)  PriessGAD cells were treated with 
HSP90α, HSP90β, or control siRNA and incubated for  48 hours as previously 
described.  Following treatment, cells were fixed in 1% paraformaldehyde, 
permeabilized, and Ab stained for total CLIP (A and C) or surface CLIP (B) 
expression by flow cytometry.  (A and B) Black line indicates control cells, dark 
gray line indicates RA treated cells, light gray line indicates GA treated cells, and 
thin gray line indicates isotype control staining.  (C) Thick black line indicates 
siRNA control treated cells, thin black line indicates HSP90α siRNA treated cells, 
hashed black line indicates HSP90β siRNA treated cells, and light gray line 
indicates isotype control staining.  Results shown are representative of at least 2 
separate experiments.  
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As previously described, the processing of Ii is dependent upon the activity of lysosomal 
proteases.  Treatment of B cells with the lysosomal protease inhibitor leupeptin results in 
LIP accumulation (224, 225).   To determine if HSP90 inhibition altered Ii processing in 
a manner similar to leupeptin, PriessGAD lysates were co-treated with or without 
leupeptin and GA.  Following theses treatments, whole cell lysates were Western 
immunoblotted for mature Ii and LIP fragment expression.  In both control and GA 
treated cells, only mature Ii was detected (Fig. 29).  Upon treatment with leupeptin, 
mature Ii and LIP fragment were detected in both control and GA treated cells (Fig. 29).  
The average relative expression as determined by densitometry revealed that mature Ii 
expression was not altered by GA, leupeptin, or GA + leupeptin treatment.  However, 
leupeptin induced LIP accumulation was decreased by 60% in GA treated cells compared 
to control treated cells.  Thus, treatment with these inhibitors appears to alter the steady 
state abundance of the intermediate LIP but not the final proteolytic product CLIP.  
Possibly, GA treatment might alter the kinetics of Ii processing by altering cellular 






















Figure 29.  Pharmacological inhibition of HSP90 alters leupeptin induced LIP 
accumulation.  PriessGAD cells were treated with either DMSO control, GA 
(0.18 µM), DMSO control and leupeptin (50 µM), or GA (0.18 µM) and leupeptin 
(50 µM) for 18 hours. (A)  WCLs of treated cells were fractionated on 12% SDS-
PAGE gels and Western immunoblotted for mature Ii, LIP, and actin.  Blot is 
representative of at least 3 separate experiments.  (B) Average relative expression 
of mature Ii and LIP expression as determined by densitometry from 3 separate 
experiments is displayed in the table.   
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To further explore this observation, PriessGAD cells were co-treated with leupeptin and 
either HSP90α or HSP90β siRNA.  Following treatment, Western immunoblotting for 
mature Ii and LIP fragment expression was performed on whole cell lysates. Only mature 
Ii expression was detected in HSP90α siRNA and control treated cells (Fig. 30A).  Upon 
leupeptin treatment of HSP90α siRNA and control treated cells, both mature Ii expression 
and LIP accumulation was detected (Fig. 30A).  Similarly, treatment with HSP90β 
siRNA and control alone resulted in detection of only mature Ii expression (Fig. 30A).  
Upon leupeptin treatment, LIP fragment accumulation was detected in both HSP90β 
siRNA and control treated cells (Fig. 30A).  The average relative expression as 
determined by densitometry revealed that mature Ii expression was not altered by either 
HSP90α or HSP90β siRNA treatment wjhen compared to control.  Leupeptin treatment of 
HSP90α siRNA, HSP90β siRNA, or controls did increase mature Ii expression (Fig. 
30B).  However, leupeptin induced LIP accumulation was unaffected by either HSP90α 
or HSP90β siRNA compared to controls (Fig. 30).   
 
While leupeptin induced LIP accumulation was affected by GA treatment, neither 
HSP90α nor HSP90β siRNA treatment appear to alter this step in Ii processing.  Previous 
results found that GA and RA treatment of cells induced a heat shock stress response 
(Fig. 13).  Neither HSP90α nor HSP90β siRNA treatment of B cells induced a heat shock 
stress response (Fig. 20).  While pharmacological inhibition of HSP90 by GA and RA 
affects MHC class II expression and function similarly to HSP90α and HSP90β siRNA 
treatment, the siRNA treatment is likely more specific than pharmacological inhibitors 
and less prone to inducing an overall stress response.  Potentially, the affects of GA on 
leupeptin induced LIP accumulation may be due to the stress response induced by this 
drug and not inhibition of HSP90.  Considering that neither pharmacological or siRNA 
treatment altered total Ii, total CLIP, or surface CLIP expression as determined by flow 
cytometry, these results suggest that Ii processing is not radically altered in cells cultured 
under these conditions (Fig. 27 and 28).  Thus, the decreased MHC class II presentation 
of GAD upon HSP90α and HSP90β inhibition is not likely a result of altered Ii 




Figure 30.  HSP90α and HSP90β inhibition does not alter leupeptin induced LIP 
accumulation.  PriessGAD cells were nucleofected with HSP90α and HSP90β 
siRNA as previously described.  After 30 hours, cell samples were split, and half 
of each set was treated with leupeptin (50 µM) for the remaining 18 hours.  (A)  
WCLs were fractionated on 12% SDS-PAGE gels and Western immunoblotted 
for mature Ii chain, LIP, and GAPDH. Blot is representative of at least 3 separate 
experiments.  (B)  Average relative expression of mature Ii and LIP expression as 
determined by densitometry from at least 2 separate experiments is displayed in 
the tables.   
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Pharmacological inhibition of HSP90 does not alter cathepsin expression, but does 
alter cathepsin activity   
Previous studies have shown that lysosomal acidic proteases systematically cleave Ii 
(111, 119, 224).  For example, cathepsin B and D are required for processing Ii as well as 
exogenous Ag for MHC class II presentation (224).  Alterations in cathepsin expression 
or protease activity could possibly explain the decreased MHC class II presentation of 
GAD upon GA and RA treatment.  To further explore the role of HSP90 in the MHC 
class II presentation pathway, the effect of pharmacological inhibition of HSP90 on 
cathepsin expression was investigated.  PriessGAD cells were treated with RA (2 µM), 
GA (0.18 µM), or DMSO solvent as a control and analyzed for cathepsin S, L, B, and D 
mRNA expression by RT-PCR.  Neither RA nor GA altered cathepsin S, L, B, or D 
mRNA expression in PriessGAD cells (Fig. 31). 
 
Figure 31.  Pharmacological inhibition of HSP90 does not alter cathepsin 
expression.  PriessGAD cells were treated with either DMSO control, RA (2 
µM), or GA (0.18 µM) for 18 hours. Following treatment, mRNA was isolated 
from cells and reverse transcribed to cDNA.  From each sample, cDNA was 
subjected to PCR to amplify cathepsin S, cathepsin L, cathepsin B, cathepsin D, 
and GAPDH sequences.  PCR products were resolved on an agarose gel with 




In addition to RNA expression, cathepsin S, S/L, and B protease activity in GA, RA, or 
DMSO treated PriessGAD cells were measured by cathepsin activity assays.  The activity 
of cathepsin S was unaffected by GA or RA treatment (Fig. 32A).  Using a substrate that 
is cleaved by both cathepsin S/L, both GA and RA treatment increased the activity of 
cathepsin S/L together when compared to DMSO control treatment (Fig. 32B).  GA and 
RA treatment of cells also decreased cathepsin B activity in PriessGAD cells (Fig. 32C).  
Cathepsin S and L are known to cleave LIP to CLIP during Ii processing.  Thus, 
increased expression of either of these enzymes might lead to more efficient LIP 




Figure 32.  Pharmacological inhibition of HSP90 altered cathepsin activity in B cells.  
PriessGAD cells were treated with either DMSO control, GA (0.18 µM), or RA (2 
µM) for 18 hours.  These cells were lysed and detergent extracted whole cell 
lysates were analyzed for cathepsin S (A), S/L (B), or B (C) protease activity.  
Results are representative of at least 3 separate experiments.   
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Inhibition of HSP90α and HSP90β does not alter HLA-DM and HLA-DO function. 
HLA-DM functions at the terminal stages of MHC class II maturation by catalyzing the 
removal of CLIP and the subsequent loading of antigenic epitopes onto MHC class II 
molecules (226).  This activity is shown schematically in figure 6.  In the presence of 
HLA-DM, the loading of antigenic epitopes onto MHC class II molecules is selective, 
favoring peptides with high affinity for MHC class II dimers (227).  Previous studies in 
the lab indicated that HLA-DM regulates MHC class II presentation of both exogenous 
and endogenous GAD Ag (132).  HSP90α and HSP90β inhibition by either the 
pharmacological inhibitors RA and GA or isotype specific siRNA, could be affecting 
HLA-DM expression and activity.  To determine if HLA-DM expression is affected by 
HSP90 inhibition, PriessGAD cells were treated with RA, GA, or DMSO solvent as a 
control and analyzed for HLA-DM expression by flow cytometry.  Neither RA nor GA 
treatment altered HLA-DM protein expression in PriessGAD cells (Fig. 33A).  
Additionally, PriessGAD cells were also treated with HSP90α, HSP90β, and control 
siRNA and analyzed for HLA-DM protein expression by flow cytometry.  HLA-DM 
protein levels were not altered by HSP90α or HSP90β siRNA treatment (Fig. 33B).   
 
In B cells, HLA-DM function is regulated by HLA-DO (51-55).  This activity is shown 
schematically in figure 6.  Changes in HLA-DO levels due to altered HSP90α and 
HSP90β function could alter overall MHC class II presentation.  To determine if HLA-
DO protein expression is affected by HSP90 inhibition, PriessGAD cells were treated 
with RA, GA, or DMSO solvent as a control and analyzed for HLA-DO expression by 
flow cytometry.  Neither RA nor GA treatment altered HLA-DO protein expression in 
PriessGAD cells (Fig. 33B).  Additionally, PriessGAD cells were also treated with 
HSP90α, HSP90β, and control siRNA and analyzed for HLA-DO protein expression by 
flow cytometry.  HLA-DO protein expression was not altered by HSP90α or HSP90β 
siRNA treatment (Fig. 33D).  These results indicated that HLA-DM and HLA-DO 
expression is not altered by either pharmacological inhibition of HSP90 or HSP90α and 
HSP90β isotype specific siRNA.  Figure 28 indicated that total and surface CLIP 
expression was not affected by either pharmacological inhibitors, RA and GA, or HSP90 
specific siRNA.  These results indicate that neither HLA-DM nor HLA-DO function is 
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altered as the level of CLIP bound by surface MHC class II molecules on cells is 
intimately tied to HLA-DM and HLA-DO function in cells.  Therefore, these results 
indicate that HLA-DM and HLA-DO protein expression and function are not affected by 
HSP90α and HSP90β inhibition.   
 
Figure 33.  Inhibition of HSP90α and HSP90β does not alter total cellular HLA-DM 
or HLA-DO expression.  PriessGAD cells were treated with DMSO as a control, 
RA (2 µM), or GA (0.18 µM) for 18 hours (A and C). PriessGAD cells were 
treated with HSP90α, HSP90β, or control siRNA and incubated for 48 hours as 
previously described (B and D).  Following treatment, cells were fixed, 
permeabilized, and stained for total HLA-DM (A and B) or total HLA-DO (C and 
D) expression by flow cytometry.  (A and C) Black line indicates control cells, 
dark gray line indicates RA treated cells, light gray line indicates GA treated cells, 
and thin gray line indicates isotype control staining.  (B and D) Thick black line 
indicates siRNA control treated cells, thin black line indicates HSP90α siRNA 
treated cells, hashed black line indicates HSP90β siRNA treated cells, and light 
gray line indicates isotype control staining.  Results shown are representative of at 
least 2 separate experiments.  
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Inhibition of HSP90α and HSP90β does not induce ER stress 
As previously described, the ER chaperones grp94 and BiP are ER homologs of 
cytoplasmic HSP90 and HSP70 respectively.  Due to the similarity between grp94 and 
HSP90, GA can bind to both of these chaperones.  Using a variety of cell lines, studies 
indicate that GA treatment can induce an ER stress response represented by an 
upregulation of ER chaperones (228).  This upregulation was due to the unfolded protein 
response and not due to any affects on HSP90.  However, additional research suggests 
that HSP90 may also be linked to the cellular transcriptional response to ER stress (214).  
Previous studies indicated that MHC class II molecules can bind to select ER chaperones 
(217).  Thus, induction of ER stress could be one explanation for the observed decrease 
in MHC class II presentation of GAD upon HSP90 inhibition.   
 
To determine if HSP90 inhibition affects ER stress, the expression of grp94 and BiP was 
examined by Western immunoblotting whole cell lysates of PriessGAD cells treated with 
pharmacological inhibitors.  Neither GA nor RA induced grp94 or BiP expression in 
PriessGAD cells with reduced HSP90 activity compared to controls (Fig. 34A).  The 
average relative expression of grp94 and BiP as determined by densitometry of at least 3 
separate experiments confirmed there was no significant affect of HSP90 inhibition on 








Figure 34.  Pharmacological inhibition of HSP90 does not induce ER stress.   
PriessGAD cells were treated with either DMSO control, GA, or RA.  (A) WCL 
from treated cells were analyzed by Western immunoblotting for expression of 
grp94 and BiP. Blot is representative of at least 3 separate experiments.  (B)  The 
average relative expression of grp94 and BiP expression +/- SEM as determined 
by densitometry of at least 3 separate experiments is displayed in the table.  
Student t tests determined no significant change in grp94 or Bip expression.   
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To further explore the effect of HSP90 inhibition on ER stress, grp94 and BiP expression 
was measured by Western immunoblotting in PriessGAD cells upon HSP90α and 
HSP90β siRNA treatment.  Neither HSP90α nor HSP90β siRNA treatment induced grp94 
or BiP expression in PriessGAD cells (Fig. 35A).  Densitometry of at least 3 separate 
experiments indicated that HSP90α and HSP90β inhibition by siRNA did not 
significantly alter the relative expression of grp94 or BiP (Fig.35B).  Taken together, 
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Figure 35.  HSP90α and HSP90β inhibition by siRNA did not induce ER stress.   
PriessGAD cells were treated with HSP90α siRNA, HSP90β siRNA, or control 
siRNA as previously described. (A)  WCL from treated cells were analyzed by 
Western immunoblotting for expression of grp94 and BiP. Blot is representative 
of at least 3 separate experiments.  (B)  The average relative expression of grp94 
and BiP expression +/- SEM as determined by densitometry from at least 3 
separate experiments is displayed in the table.  Student t tests determined no 





Pharmacological inhibition of HSP90 does not induce HSP90 secretion 
While HSP90 is located primarily in the cytoplasm of cells, a study in B cells found that 
heat stress induced enrichment of HSPs in exosomes, including HSP90 (229).  HSP70, 
which can associate with HSP90, was found to be secreted by tumor cells through a 
pathway involving lysosomal endosomes (197).  Notably, another intracellular 
chaperone, HSC70 is found both in the cytoplasm and endosomes/lysosomes with studies 
suggesting it translocates into the endosomal network in an ATP-dependent process 
(166).  Whether HSP90 uses a similar pathway to access the endosomal network is 
unknown.  Several studies have suggested peptide-HSP90 complexes released by tumors 
can promote MHC class I presentation (137, 140, 144, 223).  Notably, islet cell stress 
including exposure to cytokines such as IL-1β is known to induce HSP90 expression 
prior to cell death (184).  The presence of extracellular HSP90 could explain the 
requirement for functional HSP90 for MHC class II presentation of exogenous GAD Ag.    
 
To determine if extracellular HSP90 is present in B cell cultures, conditioned B cell 
media, fresh media, and individual media components were examined for the presence of 
HSP90.  PriessGAD, Priess, Frev, and FrevSMA cells were cultured for 48 hours.  After 
48 hours, the conditioned media was collected and fractionated on a 10% SDS-PAGE gel 
along with fresh B cell media, IMDM media, serum, H-SFM media, and WCL from 
PriessGAD cells as a control.  Western immunoblotting did not detect any secreted 
HSP90 from conditioned B cells (Fig. 36A).  Exogenous HSP90 was also not detected in 
fresh B cell media or its components as indicated by Western immunoblotting (Fig. 36A).  
These results indicate that HSP90 is not likely secreted from B cells at measurable levels 
upon cell culture.   
 
While HSP90 is not secreted by B cells during steady state conditions, treatment of cells 
with pharmacological inhibitors of HSP90 could possibly induce HSP90 secretion.  To 
determine if HSP90 is secreted upon stress conditions in B cells, PriessGAD cells were 
treated with either GA (0.18 µM), RA (2 µM), or DMSO solvent as a control.  
Conditioned media from these cell treatments was concentrated and examined for the 
presence of HSP90 by Western immunoblotting.  Neither GA nor RA induced HSP90 
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secretion in PriessGAD (Fig. 36B).  While HSP90 was not secreted by B cells, we cannot 
rule out that these drugs promoted delivery or retention of HSP90 in endosomes and 




Figure 36.  Pharmacological inhibition of HSP90 does not induce HSP90 secretion 
by B cells.  (A) Conditioned media from Priess (P), PriessGAD (PG), Frev (F), 
and FrevSMA (FS) cells; fresh IMDM cell media plus serum; fresh cell media 
components IMDM or serum; and an the H-SFM cell media was concentrated 
from 13 ml into approximately 50 µl.  Concentrated samples were ran on 10% 
SDS PAGE gel along with PriessGAD WCL as a positive control. Blots were 
probed for HSP90.  (B) PriessGAD cells were treated with either DMSO control, 
GA, or RA for 18 hours.  After treatment, 75 µl of media was fractionated on 10% 
SDS PAGE gels along with PriessGAD WCL as a positive control.  Results are 
representative of at least 2 separate experiments. 
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As an alternate approach, whether exogenous HSP90 could enhance exogenous GAD 
presentation was tested.  Purified, recombinant human GAD Ag was pre-complexed with 
purified HSP90 at a 1:1 molar ratio prior to the addition to Priess cells.  MHC class II 
presentation of GAD Ag using HSP90/GAD pre-complexes was compared to 
presentation of GAD in the absence of exogenous HSP90.   Pre-complexing purified 
HSP90 with exogenous GAD in vitro prior to addition to Priess cells slightly enhanced 
GAD presentation (Fig. 37).  Notably this effect was only seen using low levels of 
HSP90 and GAD Ag (Fig. 37A).  At higher concentrations, the presence of HSP90 did 
not enhance GAD Ag presentation (Fig. 37B).   
 
Figure 37.  Low concentrations of exogenous HSP90 enhance MHC class II 
presentation of exogenous GAD Ag.  Purified HSP90 and purified GAD Ag (3:1 
molar ratio), purified GAD Ag in PBS, or HSP90 in PBS were incubated for 24 
hours in order to permit protein complex formation.  (A)  Priess cells were treated 
with low concentrations of HSP90/GAD (0.00192µM/ 0.00064 µM), GAD Ag 
(0.00064 µM), or HSP90 (0.00192 µM) for 16 hours.  (B) Priess cells were 
treated with high concentrations of HSP90/GAD Ag (0.0192 µM/0.0064 µM), 
GAD Ag (0.0064 µM), or HSP90 (0.0192 µM) for 16 hours.  MHC class II 
presentation of exogenous GAD was measured by T cell assay.  Control assays 
were carried out as in figure 8. Results are displayed as proliferation above 
background. Results are representative of at least 3 separate experiments.   
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Chapter 3.  Implication of HSP70 as a possible chaperone for SMA in B cells 
Studying the role of HSP90 in MHC class II presentation revealed the potential 
requirement for another HSP, HSP70, in the presentation of some cytoplasmic Ags.  The 
human B-LCL Frev expresses both the HLA-DR4 and HLA-DR1 MHC class II alleles.  
Unlike Priess cells, Frev cells lack the secretory Ig kappa light chain. Thus, Frev cells 
were transfected with a plasmid encoding the cDNA for SMA, a mutant cytoplasmic 
form of the Ig light chain κ4.  FrevSMA cells express endogenous, cytoplasmic SMA Ag 
which can be processed and presented by MHC class II molecules.  SMA was isolated 
from a patient with amyloidosis (207, 230).  Amyloidosis is a group of diseases 
characterized by the assembly of protein fibrils that are deposited extracellulary in 
various organs and tissues.  Almost immediately following SMA protein synthesis, this 
amyloid protein misfolds and is translocated out of the ER to the cytosol.  Once in the 
cytosol, SMA is ubiquitinated and is either degraded by cytoplasmic proteases or 
aggregates in inclusion bodies.  The molecular events that govern SMA escape from the 
cell’s quality control system and which lead to protein fibril formation are unknown.  
However, HSP70 has been shown to promote the proteasomal degradation of SMA and 
potentially regulate fibril accumulation (207).  Two SMA peptide epitopes are formed 
upon SMA proteasome processing and translocated by CMA into endosomes for 
complexing with MHC class II molecules.  These two SMA epitopes are termed SMA188-
203 and SMA145-159  in FrevSMA cells.  Similar kappa I and kappa II epitopes are 
presented by Frev cells incubated with wild type IgG or Ig kappa Ags.  Thus like GAD, 
endogenous and exogenous forms of Ig kappa yield identical peptides for MHC class II 
presentation despite differences in their intracellular location and initial processing.  
Studies here examined the role of HSP90 and HSP70 in MHC class II presentation of 
SMA Ag.   
 
Studies have detected extracellular HSP70:peptide complexes in MHC class II –enriched 
compartments after receptor-mediated endocytosis (208).  HSP70 has been shown to 
interact with MHC class II molecules (209).  Studies also suggest HSP70 mediated 
enhancement of MHC class II restricted peptide presentation (209, 231).  And relevant to 
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autoimmunity, HSP70 has been shown to promote myelin autoantigen presentation by 
MHC class II molecules (139).    
 
Pharmacological inhibition of HSP90 enhances MHC class II presentation of SMA 
To determine the effect of HSP90 inhibition on MHC class II presentation of endogenous 
SMA, FrevSMA cells were treated with increasing concentrations of GA and RA for 18 
hours.  MHC class II presentation of SMA was enhanced in a dose-dependant manner 
with both GA and RA (Fig. 38).  These results are in contrast to endogenous GAD 
presentation by MHC class II molecules, which was decreased by GA and RA treatment 
(Fig. 9).   
 
Figure 38.  Pharmacological inhibition of HSP90 increases MHC class II 
presentation of endogenous SMA.  FrevSMA cells were treated with DMSO as 
a negative control or increasing concentrations of GA (A) or RA (B) for 18 hours. 
MHC class II presentation of endogenous SMA was analyzed by T cell assays. 
Control assays were carried out as in Figure 8.  Here, the negative control 
indicates HT2 cell proliferation without IL-2 addition. Results are representative 




The effect of pharmacological inhibition of HSP90 on MHC class II presentation of 
epitopes from exogenous whole IgG Ag was also analyzed.  Frev cell lines  were treated 
with GA (0.18 µM), RA (2 µM), or DMSO solvent as a control for 18 hours with varying 
concentrations of exogenous whole IgG Ag added after 2 hours of drug treatment.  MHC 
class II presentation of kappa I or kappa II epitopes from exogenous whole IgG Ag was 
detected using T cell assays.  Both GA and RA increased MHC class II presentation of 
the subdominant kappa I epitope from exogenous whole IgG Ag (Fig. 39 A and B).  
MHC class II presentation of the dominant kappa II epitope from exogenous whole IgG 
Ag was also increased by both GA and RA treatment (Fig.39 C and D).   
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Figure 39.  Pharmacological inhibition of HSP90 increases MHC class II 
presentation of exogenous IgG kappa Ag.  Frev cells were treated with DMSO 
as a control, GA (0.18 µM) (A and C), or RA (2 µM) (B and D) for 18 hours.  
After 2 hours of treatment, whole IgG kappa Ag was added to B cells at 10, 20, or 
30 µM concentrations.  After 18 hours,  B cell MHC class II presentation of kappa 
I (A and B) and kappa II (C and D) epitopes from exogenous IgG kappa Ag was 
measured by T cell assays.  Control assays were carried out as in Figure 8.  
Results are representative of at least 3 separate experiments.  
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GA and RA treated Frev cells were also pulsed with exogenous kappa I and kappa II 
peptides and MHC class II presentation of each of these peptides was detected using T 
cell assays.  When low concentrations of exogenous kappa I peptide was added, both RA 
and GA increased MHC class II presentation of kappa I epitope (Fig. 40 A and B).  When 
higher concentrations of peptide were added, neither RA nor GA affected kappa I epitope 
presentation (Fig. 40 A and B).  MHC class II presentation of kappa II peptide was also 
increased upon RA and GA treatment at low peptide concentrations (Fig 40 C and D).  
Again, when higher concentrations of peptide were added, GA and RA did not alter 
peptide presentation (Fig. 40 C and D).   
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Figure 40.  Pharmacological inhibition of HSP90 increased MHC class II 
presentation of exogenous IgG kappa epitopes.  Frev cells were treated with 
GA (0.18 µM) (A and C), RA (2 µM) (B and D), or DMSO as a control for 18 
hours.  After 2 hours of treatment, synthethic kappa I and kappa II peptide was 
added to cells at 1, 5, and 10 µM concentrations.  After 18 hours, MHC class II 
presentation of kappa I (A and B) and kappa II (C and D) epitopes from 
exogenous kappa peptides was measured by T cell assays.  Results are 





Pharmacological inhibition of HSP90 induces a heat shock stress response 
Previous results with PriessGAD cells indicated that both GA and RA induce a heat 
shock stress response.  Both GA and RA induced the expression of HSP70 and HSP40 in 
PriessGAD cells (Fig. 13).  FrevSMA cells were examined for a heat shock stress 
response upon GA and RA treatment.  Similar to the results with PriessGAD cells, both 
GA and RA induced a heat shock stress response in FrevSMA cells (Fig. 41A).  Both RA 
and GA treatment induced HSP70 and HSP40 expression.  Densitometry revealed that 
HSP70 expression was enhanced by 700% to 1100% (Fig. 41B).  Induction of heat shock 




Figure 41.  Pharmacological inhibition of HSP90 induces a stress response in 
FrevSMA B cells. FrevSMA cells were treated with either RA (2 µM), GA (0.18 
µM), or DMSO as a control for 18 hours.  (A) Whole cell lysates from treated 
cells were fractionated on 10% SDS-PAGE gels and Western immunoblotted for 
HSP90, HSC70, HSP70, HSP40, and actin protein expression.  (B) Densitometry 
of the representative experiment.  Results are representative of at least 3 separate 
experiments.   
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To determine if heat shock could mimic the heat shock stress response in FrevSMA cells 
upon GA or RA treatment.  FrevSMA cells were subjected to heat shock and measured 
for HSP70 and HSP40 expression by Western immunoblotting.  Upon heat shock at 40°C 
and 42°C, both HSP70 and HSP40 expression was induced in FrevSMA cells (Fig. 42).  
Thus, heat shock can mimic the heat shock stress response upon RA and GA treatment in 
both PriessGAD and FrevSMA cells.   
Average Relative Expression of HSP/HSC
121% +/- 5%118% +/- 15%100%HSC70/Actin
111% +/- 8%102% +/- 21%100%HSP40/Actin
598% +/- 229% *205% +/- 45% *100%HSP70/Actin














Figure 42.  Heat stress induces HSP expression in FrevSMA cells.  FrevSMA cells 
were incubated for 20 minutes at 37, 40, or 42°C followed by a 24 hour 
incubation at 37°C.  (A) Whole cell lysates from these cells were fractionated on 
10% SDS-PAGE gels and Western immunoblotted for HSP90, HSC70, HSP70, 
HSP40, and actin protein expression. The results are representative of at least 3 
separate experiments.  (B) The table depicts the average relative expression of 
HSP/HSC +/- SEM as determined by densitometry of at least 3 separate 




Subjecting PriessGAD cells to heat shock did not alter MHC class II presentation of 
endogenous GAD, endogenous kappa, exogenous HSA Ag, and exogenous HSA peptide 
(Fig. 15).  To determine if MHC class II presentation of endogenous SMA is altered by 
heat shock, FrevSMA cells were incubated at 37 or 42°C for 20 minutes followed by a 24 
hour incubation at 37°C.  Following heat shock, FrevSMA cells were measured for MHC 
class II presentation of endogenous SMA by T cell assays.  In contrast to endogenous 
GAD presentation, heat shock enhanced MHC class II presentation of endogenous SMA 
(Fig. 43).   
 
Figure 43.  Heat stress enhances MHC class II presentation of endogenous SMA.  
FrevSMA cells were incubated for 20 min at 37 or 42°C followed by a 24 hr 
incubation at 37°C.  After incubation, MHC class II presentation of endogenous 
SMA epitope was measured by T cell assay.  Results are representative of at least 
3 separate experiments.  
 
Pharmacological inhibition of HSP90 does not alter MHC class II expression 
As previously stated, HSP90 overexpression in macrophages was found to enhance MHC 
class II dimer stability while GA and RA treatments decreased dimer stability (142).  
Both HSP90 overexpression and inhibition were reported not to alter surface and total 
MHC class II protein expression in these murine cells (142).  However, Western 
immunoblotting of PriessGAD cells treated with either GA or RA found that MHC class 
II monomer expression and dimer stability was not affected by pharmacological 
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inhibition of HSP90 (Fig. 16).  Flow cytometric analysis of GA or RA treated PriessGAD 
cells confirmed the lack of affect on both surface and total MHC class II levels (Fig. 17).  
To evaluate whether GA or RA inhibition of HSP90 altered MHC class II expression 
levels in FrevSMA cells, FrevSMA cells were treated with either GA (0.18 µM), RA (2 
µM), or DMSO as a control and Western immunoblotted for MHC class II dimer 
expression.  Neither GA nor RA significantly altered the steady state levels of MHC class 
II dimers (Fig. 44).  These results indicate that the increase in MHC class II SMA Ag 
presentation observed with GA or RA treatment is not due to alterations in MHC class II 
dimer expression or stability in B cells.   
 
 
Figure 44.  Pharmacological inhibition of HSP90 does not alter MHC class II 
expression in FrevSMA B cells.  FrevSMA cells were treated with either RA (2 
µM), GA (0.18 µM), or DMSO as a control for 18 hours.  (A) Whole cell lysates 
from treated cells were fractionated on 10% SDS-PAGE gels and Western 
immunoblotted for MHC II dimers and GAPDH protein expression. Blot is 
representative of at least 3 separate experiments.  (B) The table depicts the 
average relative expression of MHC II dimers +/- SEM as determined by 
densitometry of at least 3 separate experiments. Statistical analysis using the 
student t tests determined no significant difference in the expression of MHC 





Pharmacalogical inhibition of HSP90 induces ER stress in FrevSMA 
As previously described, the ER chaperones grp94 ad BiP are ER homologs of 
cytoplasmic HSP90 and HSP70 respectively.  Due to the similarity between grp94 and 
HSP90, GA can bind to both of these chaperones.  Previous studies indicate that GA 
treatment can induce an ER stress response represented by an upregulation of ER 
chaperones in certain cell lines (228).  Neither GA nor RA treatment induced an ER 
stress response in PriessGAD cells (Fig. 34).  However, it was unknown whether ER 
stress is induced in FrevSMA cells upon GA and RA treatment.  An induction of ER 
stress could be one explanation for the observed decrease in MHC class II presentation of 
GAD upon HSP90 inhibition.   
 
To determine if HSP90 inhibition affects ER stress in FrevSMA cells, the expression of 
grp94 and BiP was examined by Western immunoblotting whole cell lysates of FrevSMA 
cells treated with pharmacological inhibitors.  Both GA and RA significantly induced 
grp94 and BiP expression in FrevSMA cells with reduced HSP90 activity compared to 
controls (Fig. 45A).  However, RA treatment enhanced the expression of both grp94 and 
BiP slightly more than GA. The average relative expression of grp94 and BiP as 
determined by densitometry of at least 3 separate experiments confirmed these results 
(Fig. 45B).  These results indicate that in contrast to PriessGAD cells, HSP90 inhibition 




Figure 45.  Pharmacological inhibition of HSP90 induces ER stress in FrevSMA 
cells.  FrevSMA cells were treated with either GA (0.18 µM) or RA (2 µM), or 
DMSO control.  A.  Whole cell lysates from treated cells were analyzed by 
Western immunoblotting for expression of grp94 and BiP.  Blot is representative 
of at least 3 separate experiments.  B.  The average relative expression of grp94 
and gp78 expression +/- SEM as determined by densitometry of at least 2 separate 
experiments is displayed in the table.  *Statistically significant as determined by 
student t tests.  
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Pharmacological inhibition of HSP90 does not induce HSP70 secretion 
Studies in tumor cells found that HSP70 was secreted by tumor cells through a pathway 
involving lysosomal endosomes (197).  Our prior study had failed to detect secreted 
HSP90 following RA and GA treatment.  Secretion of HSP70 could potentially explain 
the enhanced MHC class II presentation of kappa I and kappa II peptides from exogenous 
Ig Ag upon GA and RA treatment.  Western immunoblotting of concentrated conditioned 
media from Priess, PriessGAD, Frev, and FrevSMA cells failed to detect any HSP90 or 
HSP70 protein (Fig. 36A and 46A).  HSP70 was also not detected in fresh media or 
media components (Fig. 46A).  Neither GA nor RA treatment induced HSP70 secretion 
by PriessGAD cells (Fig. 36B).  Likewise, HSP70 was not detected in the conditioned 
media of PriessGAD cells upon RA and GA treatment (Fig. 46B).  As a control, blots 
were stained with Ponceau S to confirm the presence of protein (Fig. 46C).  These results 




Figure 46.  Pharmacological inhibition of HSP90 does not induce HSP70 secretion 
by B cells.  (A)  Conditioned media from Priess (P), PriessGAD (PG), Frev (F), 
and FrevSMA (FS);  fresh IMDM cell media plus serum; fresh IMDM media or 
serum components; and H-SFM media was concentrated from 13 ml into 50 µl.  
Concentrated samples were fractionated on 10% SDS PAGE gels along with 
PriessGAD WCL as a positive control. Blots were probed for HSP70.  (B and C)  
PriessGAD cells were treated with either DMSO control, GA, or RA for 18 hours.  
After treatment, 75 µl of conditioned media was fractionated on 10% SDS PAGE 
gels along with PriessGAD WCL as a positive control.  In panel B, blot was 
probed for HSP70 and GAPDH.  In panel C, blot was stained with Ponceau S for 
total protein for a control.  The results are representative of at least 3 separate 
experiments.   
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Pharmacological inhibition of HSP90 alters leupeptin-induced LIP accumulation 
In PriessGAD cells, treatment with GA decreased leupeptin induced LIP accumulation 
(Fig. 29).  GA treated FrevSMA cells were also examined for leupeptin induced LIP 
accumulation.  As shown with PriessGAD cells, treatment of FrevSMA cells with GA 
decreased leupeptin induced LIP accumulation (Fig. 47).  These results are similar to 
those seen with the B cell line PriessGAD.     
 
 
Figure 47.  Pharmacological inhibition of HSP90 alters leupeptin induced LIP 
accumulation.  FrevSMA cells were treated with either DMSO control, GA (0.18 
µM), DMSO control and leupeptin (50 µM), or GA (0.18 µM) and leupeptin (50 
µM) for 18 hours.  (A) WCL of treated cells were ran on 12% SDS-PAGE gel and 
Western immunoblotted for mature Ii, LIP, and Actin.  (B)  Densitometry of the 
representative experiment.  Results are representative of at 2 separate 
experiments.   
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Chapter 4.  Type B insulin resistance developing during interferon α therapy  
Interferon α is an inflammatory cytokine belonging to the type I interferon family.  The 
cellular stress of viral infection induces interferon α production by leukocytes.  Interferon 
α  has been shown to play key roles in defending the host immune system during a viral 
infection by binding to cell surface receptors on host cells and making conferring 
resistance to viral infection (232).  Due to its potent anti-viral effects, interferon α has 
been used either alone or in conjunction with additional anti-viral medications for the 
treatment of chronic hepatitis infection (233).  While interferon α treatment is effective in 
treating chronic hepatitis C infection, this study indicates that type B insulin resistance 
can occur due to interferon α therapy.   
 
Introduction 
Type B insulin resistance is a rare syndrome caused by the production of autoantibodies 
to the insulin receptor.  These autoantibodies were initially described in patients 
diagnosed with both diabetes and extreme insulin resistance (234).  However, current 
studies have shown that anti-insulin receptor antibodies can cause abnormalities of 
glucose homeostasis ranging from profound insulin resistance to life-threatening 
hypoglycemia (235).  Most patients with insulin receptor autoantibodies have an 
underlying connective tissue disorder such as systemic lupus erythematosis.  Research 
has described autoimmune hypoglycemia with insulin receptor autoantibodies as a 
paraneoplastic syndrome in Hodgkin’s lymphoma and multiple myeloma (236, 237).  
Autoimmune hypoglycemia has been reported as arising after heterologous bone marrow 
transplantation (238).  The National Institutes of Health evaluated the demographics of a 
series of 24 patients with type B insulin resistance or autoimmune hypoglycemia and 
determined that 83% were women and 88% were African Americans (235).  Studies 
confirm that most patients with type B insulin resistance develop acanthosis nigricans, 
and women of reproductive age usually have ovarian hyperandrogenism (235, 239).      
 
Case report 
The patient in this study was a 55 year old African American male diagnosed with 
hepatitis C, genotype 1b.  A biopsy of his liver revealed chronic hepatitis with minimal 
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activity and mild fibrosis.  The patient began treatment with pegylated interferon -1a 
and ribavirin. At the beginning of treatment, his hepatitis C viral RNA titer was 3950 
KIU/mL.  He had no personal history of diabetes mellitus, and his fasting plasma glucose 
before interferon treatment was 112 mg/dL.  Two months after starting therapy, he 
developed anemia, which was managed with erythropoietin  and a reduction of his 
ribavirin.  After 6 months of treatment, his weight had fallen 16 kg and viral RNA was 
not detectable.  Two months later, he presented with symptoms of polyuria, polydipsia, 
weakness, blurred vision, and fatigue.  Over the preceding month, his weight had fallen 
another 11 kg, and his weakness was so profound that he was unable to tie his shoes.  At 
this time, he was admitted to the hospital for treatment.  Upon admission, laboratory 
testing was performed on his serum and urine.  His serum glucose was 405 mg/dl, CO2 
was 24 mmol/L, and anion gap was 10 mmol/L.  Urine ketones were 1+, and his serum 
hemoglobin A1c was 9.3%.  His serum creatinine fell to 0.8 mg/dl with aggressive 
hydration.  His serum bilirubin, AST, ALT, alkaline phosphatase, amylase, and lipase 
levels were normal.  Interferon and ribavirin treatment was discontinued.  Subcutaneous 
insulin was started and increased over three days to a daily dose of 180 units; however, 
his blood glucose levels still ranged from 300 to over 600 mg/dL.  An insulin infusion 
was started and titrated over two days to 52 units per hour, but his serum glucose levels 
were still 230-300 mg/dL.   
 
At this point, the patient was transferred to our institution.  A physical examination of the 
patient revealed a thin, African American male with a weight of 68 kg, and a height of 
170 cm.  He was in no acute distress with a blood pressure was 114/72 mm Hg.  His 
sclerae were anicteric.  While his abdomen was soft and nondistended, his right upper 
quadrant was mildly tender.  He had a palpable liver edge 4 cm below the costal margin.  
The patient did not have acanthosis nigricans, spider angiomas, palmar erythema, or 
splenomegaly.  His insulin infusion was increased to 125 units/hour, but his blood 
glucose levels still ranged from 170 to 430 mg/dL.  Lower values were present after 
fasting overnight while higher readings were detected through the day.  This patient was 
now suspected of developing type B insulin resistance.  After a week on intravenous 
insulin treatment, he was transitioned to U500 regular insulin at a dosage of 300 units 
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QID (4 times a day).  His blood glucose levels then ranged from 110 to 300 mg/dL.  
During his third week in the hospital, he developed bilateral facial weakness on the right 
right side, right-sided facial numbness, and weakness of the right lateral rectus.  An MRI 
of his brain was normal.   His cerebrospinal fluid was examined and revealed no white 
blood cells, nonreactive VDRL, negative viral and bacterial cultures, angiotensin 
converting enzyme activity 3 units (reference range < 10), glucose 114 mg/dL (reference 
interval 40 - 70), and protein 70 mg/dL (reference interval 15 - 45).  Prednisone, 40 mg 
daily for 5 days, and acyclovir was used to treat his polycranial neuropathy, and partial 
improvement of the neuropathy was noted one week later.  During his prednisone 
treatment, he was switched back to an insulin infusion with frequent glucose monitoring 
because of concern that his insulin requirements might decline dramatically.  However, 
his blood glucose levels and insulin requirement only increased.  After 4 weeks, his 
glucose levels ranged from 70 to 260 mg/dL, and he was discharged home on U500 
insulin at a dosage of 400 units QID.   
 
To confirm that the patient developed type B insulin resistance, his serum was assayed 
for the presence of anti-insulin antibodies using recombinant human insulin receptor in an 
immunoprecipitation assay (235).  Detergent-solubilized membranes of CHO/IR cells 
expressing human insulin receptor (IR) were the source of insulin receptor used in these 
assays (240).  Patient sera and pooled healthy donor sera used as a control were added to 
solubilized CHO/IR membranes, and any resulting IR-antibody complexes precipitated.  
The precipitated human antibodies (pellets) and the remaining soluble cell extracts 
(supernatants) were probed by Western blotting with commercially obtained antibodies to 
insulin receptor -subunit (Fig. 48).  Parallel immunoprecipitations of detergent 
solubilized membranes from parent CHO cells, which do not express insulin receptor, 
were performed as controls in all cases.  An intense band corresponding to insulin 
receptor α-subunit was present in antibody precipitates formed with patient serum and 
solubilized CHO/IR membranes (Fig. 48A).  The insulin receptor -subunit was not 
detected in precipitates with control CHO membranes or precipitates with pooled human 
serum from healthy donors.  The insulin receptor α -subunit was detected by Western 
immunoblotting of the IP supernatants from CHO/IR membrane incubation with pooled 
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human sera and to a lesser extent with patient serum (Fig. 48B).  Neither the insulin 
receptor α -subunit nor insulin receptor β-subunit was detected in CHO membrane 
controls.  These results confirmed that the patient did develop auto-antibodies to insulin 





Figure 48.  Anti-insulin Abs were detected in original patient serum.  Solubilized 
CHO/IR and CHO cell membrane lysates were incubated overnight at 4°C with 
50 µl of either patient sera or control pooled human sera prior to a 1 hour 
incubation with protein-G sepharose. Precipitated antibody complexes (pellets) 
(A) and residual soluble proteins (IP supernatants) (B) were analyzed by western 
blotting with a commercial anti-insulin receptor α Ab. Results representative of at 
least 3 separate experiments.   
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During his hospitalization, his sera was assayed for the presence of additional islet cell 
antibodies and glutamic acid decarboxylase antibodies.  Both tests were negative. His C-
peptide level was 2.1 ng/mL, and his insulin antibodies levels were 4.2 units/mL 
(reference range < 5.0).  His serum was also analyzed for anti-nuclear antibodies and 
screened for antibodies to extractable nuclear antigens (SM, RNP, Ro/SS-A, La/SS-B, 
Scl-70, and Jo-1), single stranded DNA, and double stranded DNA.  All results were 
negative.  His erythrocyte sedimentation rate was 32 mm/hr (reference range < 20), and 
his serum protein electrophoresis was normal.  His TSH level was 1.45 µIU/mL with 
normal free T4 and free T3 levels.  Several early morning measurements of his cortisol 
and ACTH levels did not suggest any pituitary-adrenal abnormality.  A fasting lipid panel 
two weeks after admission showed a cholesterol level of 206 mg/dL, triglyceride level of 
68 mg/dL, HDL level of 58 mg/dL, and LDL level of 135 mg/dL.  These additional tests 
further supported a diagnosis of type B insulin resistance.   
 
During the first three months after his discharge from the hospital, he reported glucoses 
fluctuating between 60 and 300 mg/dL.  His insulin injection was reduced to 50 units 
QID.  Four months after his discharge, the patient experienced two episodes of severe 
hypoglycemia, one of which required medical treatment in an emergency room.  His 
insulin injection was reduced to 30 units/day.  Six months after discharge, he had 
returned to his pre-interferon weight of 96 kg and was only taking 15 units of insulin/day.  
Nine months after discharge, he reported blood glucose levels ranging between 90 and 
190 mg/dL.  His hemoglobin A1c level was 5.7%.  Two years after discharge, his insulin 
treatment was discontinued.  His hemoglobin A1c level was 5.9%, and his blood glucose 
levels ranged from 90-160 mg/dL.  Over a one year period, his cranial neuropathies had 
resolved.  Eighteen months after discharge, his hepatitis C viral RNA titer had returned to 
pretreatment levels.  It was suspected that the patient’s severe insulin resistance had 
spontaneously resolved.   
 
To confirm a spontaneous recovery, the patient’s serum post-treatment was assayed for 
the presence of anti-insulin receptor antibodies.  Pre-treated patient sera, post-treated 
patient sera, and pooled healthy donor sera were added to solubilized CHO/IR 
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membranes, and any resulting IR-antibody complexes precipitated.  The precipitated 
human antibodies (pellets) and the remaining soluble cell extracts (supernatants) were 
probed by Western blotting with commercially obtained antibodies to insulin receptor -
subunit and insulin receptor β-subunit (Fig. 49 A and B).  Parallel immunoprecipitations 
of detergent solubilized membranes from parent CHO cells, which do not express insulin 
receptor, were performed as controls in all cases.  An intense band corresponding to 
insulin receptor α -subunit and insulin receptor β-subunit was present in antibody 
precipitates formed with pre-treatment patient serum and solubilized CHO/IR membranes 
(Fig. 49A).  Neither insulin receptor α -subunit nor insulin receptor β-subunit was 
detected in precipitates with control CHO membranes or precipitates with post-treatment 
patient sera and pooled human serum from healthy donors.  Western immunoblotting of 
the IP supernatants from CHO/IR membrane incubation with pre-treatment patient sera, 
post-treatment patient sera, and pooled human sera detected both insulin receptor -
subunit and insulin receptor β-subunit (Fig. 49B).  Neither the insulin receptor -subunit 
nor insulin receptor β-subunit was detected in CHO membrane controls. These results 
failed to detect anti-insulin antibodies in the post-treated sera of the patient, suggesting 
that the patient no longer produced autoantibodies to the insulin receptor.  Thus, these 




Figure 49.  Anti-insulin Abs were detected in original patient serum, but not post-
recovery serum.  Solubilized CHO/IR and CHO cell membrane lysates were 
incubated overnight at 4°C with 50 µl of either pre-recovery patient sera (Pre-Pt.)  
post-recovery (Post-Pt.) patient sera, or control pooled human sera (Neg) prior to 
a 1 hour incubation with protein-G sepharose. Precipitated antibody complexes 
(pellets) (A) and residual soluble proteins (IP supernatants) (B) were analyzed by 
western blotting with anti-insulin receptor α and anti-insulin receptor β Ab.  
Solubilized CHO/IR and CHO cell membranes were run as a positive control.  
Results are representative of at least 3 separate experiments.   
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Discussion 
As previously mentioned, interferon α has been used either alone or in conjunction with 
additional anti-viral medications for the treatment of chronic hepatitis infection and some 
malignancies (233).  However, interferon α treatment is associated with a variety of 
autoimmune complications, among which, thyroid autoimmunity is most common (241).  
In several recent studies of hepatitis C patients treated with interferon , the average 
incidence of hyper- or hypothyroidism was found to be 6% (242).  While some of those 
patients have destructive thyroiditis without evidence of thyroid autoimmunity, the 
majority of patients have autoimmune thyroid dysfunction (242, 243).  Approximately 
50% of patients with interferon-induced autoimmune hypothyroidism and a smaller 
percentage of those with hyperthyroidism remit after discontinuation of interferon α 
treatment (242).  Numerous other autoimmune conditions have been reported with 
interferon  therapy; they include TID, systemic lupus erythematosis, myasthenia gravis, 
celiac disease, autoimmune hepatitis, psoriasis, vitiligo, hemolytic anemia, 
thrombocytopenia, and sarcoidosis (241, 244, 245).  Interferon α -induced autoimmune 
disease tends to occur in individuals that have a higher baseline risk.  Patients are much 
more likely to develop overt disease while taking interferon α if they are genetically 
predisposed to thyroid or islet autoimmunity, or with thyroid or islet cell autoantibodies 
at commencement of therapy (242, 245). 
 
The majority of patients that develop diabetes while receiving interferon α therapy have 
TID with autoantibodies to islet cell antigens (245).  Studies have shown that chronic 
hepatitis C infection also causes insulin resistance.  Patients with hepatitis C have a 
higher prevalence of type 2 diabetes and impaired fasting glucose (246). Moreover, 
hepatitis C patients who experience a sustained virologic response to interferon therapy 
have a lower incidence of glucose abnormalities than those who do not respond (247). 
However, hepatitis C does not cause insulin resistance of the magnitude seen in this case; 
the development of type B insulin resistance during interferon therapy is distinctly 
unusual.   There is a case study from Japan of a man who developed diabetes with insulin 
receptor autoantibodies during interferon-α treatment for hepatitis C (248).  Islet 
autoantibodies were not detected in his serum.  His clinical course was characterized by 
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frequent hypoglycemia during treatment with relatively low doses of insulin.  A few 
months after discontinuation of interferon therapy, insulin receptor antibodies could no 
longer be detected, but his diabetes did not resolve.  Thus, the contribution of these 
autoantibodies to his diabetes is not clear.  A brief report from India describes the case of 
a woman with type 2 diabetes developing marked hyperglycemia during interferon 
treatment for chronic hepatitis C (249).  Even with insulin doses as high as 700 units/day, 
the hyperglycemia did not respond to treatment.  After discontinuation of interferon 
therapy, the extreme insulin resistance remitted.  Although, measurements of insulin 
receptor and other autoantibodies were not reported in her case, hyperglycemia refractory 
to such high insulin doses is consistent with type B insulin resistance.   
 
Insulin receptor autoantibodies have been shown to cause both hyperglycemia and 
hypoglycemia.  This variability in clinical presentation is due to the ability of insulin 
receptor antibodies to act as either agonists or antagonists of the insulin receptor (235, 
250).  Insulin receptor antagonism can manifest as severe hyperglycemia refractory to 
massive doses of insulin.  Stimulation of the insulin receptor causes hypoglycemia, which 
can be life-threatening (235).  In some cases, patients with hyperglycemia due to type B 
insulin resistance can develop severe hypoglycemia later in the course of their illness 
(235).  However, there are also reports of patients with systemic autoimmune disease 
producing insulin receptor autoantibodies and reporting no obvious abnormality of 
glucose metabolism (251).  It is unknown whether these simply represent antibodies that 
bind insulin receptors without altering insulin signaling, or whether these patients are at 
risk of developing autoimmune hyperglycemia or hypoglycemia in the future. 
 
In the United States, type B insulin resistance and autoimmune hypoglycemia are much 
more common in African Americans and women (235).  Most reported cases have 
occurred in patients with other autoimmune diseases such as systemic lupus 
erythematosis (250, 252).  In the case study presented here, the patient’s polycranial 
neuropathy may have had an autoimmune basis.  Cranial neuoropathies can occur in 
patients with systemic autoimmunity; there are some case reports of Bell’s palsy arising 
during interferon and ribavirin therapy (253-255).  There is also an increased incidence of 
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cranial neuropathies in diabetes (256).  It is unknown whether this patient’s polycranial 
neuropathy was caused by autoimmunity, diabetes, or another etiology.  While acanthosis 
nigricans is present in most patients with type B insulin resistance, it was not detected in 
this patient.  Steroids and other immunosuppressive therapies such as azathioprine, 
cyclophosphamide, cyclosporine, mycophenolate, and rituximab, sometimes in 
combination with plasmapheresis have all been used as treatment for the underlying 
autoimmunity in type B insulin resistance (235, 250, 257-259).  Type B insulin resistance 
has a high spontaneous remission rate.  Therefore, it is difficult to conclusively attribute 
improvements in these reports to the immunosuppressive therapy (235).  Because of 
concern that his response to the interferon might be compromised and because his insulin 
resistance appeared to be improving on its own, there was initial reluctance to use 
immunosuppressive therapy or plasmapheresis in our patient.  When he did eventually 
receive steroids for cranial polyneuropathy, his glycemic control only worsened.  In some 
cases, patients with type B insulin resistance develop autoimmune hypoglycemia later in 
the course of their illness.  In this study, the patient had two episodes of severe 
hypoglycemia, which reflect resolution of his insulin resistance, and they did not recur 
after a sharp reduction of his insulin dose.  In this case, the severe insulin resistance 
remitted spontaneously over a 6 month period after interferon was discontinued. 
 
Conclusion 
This case demonstrates that insulin receptor autoantibodies and type B insulin resistance 
can occur as a complication of interferon α therapy.  In patients receiving interferon α 
therapy who develop new hyperglycemia or hypoglycemia with no evidence for 
autoimmunity to islet antigens, the possibility of insulin receptor autoantibodies should 
be considered. 
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DISCUSSION AND FUTURE CHALLENGES 
MHC class II molecules function to present antigenic peptides to CD4+ T cells.  
Typically, MHC class II molecules present peptides derived from exogenous sources via 
the classical presentation pathway.  In this pathway, exogenous Ags or membrane Ags 
found at the cell surface are delivered into the endosomal network and processed into 
peptide fragments by endosomal/lysosomal enzymes prior to loading onto MHC class II 
molecules.  However, some endogenous cytoplasmic and nuclear Ags including tumor, 
viral, or self proteins have also been found to be sources for peptides presented by MHC 
II molecules.  Such alternative pathways of MHC class II presentation are not well 
defined or understood.  Studies suggest that specific heat shock protein family members 
may play a role in Ag processing and the subsequent presentation of antigenic peptides 
by MHC class II molecules.  The studies presented here implicate HSP90 as well as 
HSP70 as regulators of MHC class II presentation for select endogenous and exogenous 
Ags.   
 
Biological functions of HSP90 and its selective role in Ag presentation 
HSP90 has been shown to play a key role in chaperoning client proteins in a variety of 
cellular processes including cell proliferation, differentiation, and apoptosis (174).  
Manipulation of HSP90 activity has been used to modulate intracellular protein folding in 
the cytoplasm and to induce the proteolysis of misfolded or mutant proteins in a variety 
of disease conditions including malignancies and neurological disorders such as 
Alzheimer’s disease, Parkinson’s disease, autoimmune encephalomyelitis, and 
polyglutamine diseases (179-182).  HSP90 inhibitors have also been tested in human 
clinical trials to promote tumor regression (181).  Recent studies have also implicated 
HSP90 as a potential regulator of both MHC class I and II Ag processing and 
presentation (142, 143).  Studies of the MHC class I pathway suggest HSP90 may guide 
Ag processing or select epitopes for presentation (141).  Yet, whether HSP90 broadly 
controls MHC class II function or modulates instead the display of select antigenic 
epitopes has not been dissected.   
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Here, inhibition of HSP90 in B cells by either pharmacological agents such as GA and 
RA or siRNA specifically decreased MHC class II presentation of both exogenous and 
endogenous GAD (Figs. 8, 10A, and 10B).  However, MHC class II presentation of 
several other endogenous and exogenous Ags was unaffected by HSP90 inhibition (Figs. 
9, 10C, 10D, 11).  Furthermore, disruption of HSP90 function or expression failed to alter 
exogenous peptide presentation by these human APCs.  Thus, HSP90 inhibition appears 
to selectively affect MHC class II presentation in an Ag specific manner.  HSPs have 
been shown to preferentially recognize certain Ags based on their sequence or structure.  
For example, HSC70 preferentially recognizes peptides containing a KFERQ like motif, 
while HSP70 preferentially binds hydrophobic residues within Ags (140, 153, 154).   
 
Studies show that HSP90 exhibits some substrate specificity, although clear motifs 
recognized by this HSP have yet to be defined (170, 174, 178).  HSP90 may also 
recognize target proteins based on conformation or folding.  The autoantigen GAD is 
well known for its hydrophobic nature and association with lipid membranes via its N-
terminus (10, 12).  Whether these properties contribute to HSP90 association with GAD 
remains unclear.  However, this study found that HSP90 interacts with both full length 
GAD Ag as well as an N-terminal truncated form of GAD Ag (Fig. 17 and data not 
shown).  Moreover, HSP90 inhibition decreased MHC class II presentation of both 
exogenous full length GAD and N-terminal truncated GAD (Figs. 10A, 10B, and data not 
shown).  Studies to examine in vivo T cell responses to GAD Ag in the presence and 
absence of HSP90 activity could prove useful in revealing if this HSP not only alters the 
efficiency but also the specificity of GAD presentation and thus the repertoire of peptides 
displayed on APCs.  Epitope profile studies could prove useful in determining if selective 
inhibition of HSP90 alters GAD processing in a manner that changes the GAD epitope 
repertoire.  Moreover, site directed mutagenesis of the GAD protein could determine 






Association of HSP90 with proteins and links to cell stress 
The physical association of HSP90 and the autoantigen GAD in cells co-expressing these 
molecules was demonstrated (Fig. 17A).  HSP90 has been shown in some cases to work 
in concert with additional HSPs as part of a multi-protein chaperone complex; therefore, 
HSP90 and GAD association in vivo may involve other HSPs.  However, incubating 
purified HSP90 with purified GAD Ag resulted in the two proteins co-
immunoprecipitating (Fig. 17B).  Previous studies found HSP90 inhibition to alter MHC 
class II presentation.  Incubation of HSP90 with OVA Ag resulted in the two proteins co-
immunoprecipitating (Fig. 17B). Incubation of HSP90 with Ig kappa light chain failed to 
show any association between these two proteins.  Taken together with the specific effect 
of HSP90 inhibition of MHC class II expression of GAD and OVA Ag, these results 
suggest that HSP90 may selectively binds to Ags.  While these results indicate that 
HSP90 and GAD Ag can bind directly, it does not rule out the association of GAD-
HSP90 complexes with other intracellular HSPs.  Potentially, complex formation 
between HSP90 and GAD may influence GAD proteolytic processing by APCs.  The 
current study suggests the latter, demonstrating that HSP90 modulates MHC class II 
presentation of select Ags such as the diabetes autoantigen GAD but not other Ags or 
peptides.  Further studies are needed to dissect the role of individual HSP90 isoforms in 
complexing with additional HSPs and the role of such complexes in regulating Ag 
presentation.     
 
Prolonged exposure of cells to HSP90 inhibitors has been shown to induce a stress 
response in some cells as manifested by increased cellular protein expression of HSP70, 
HSP90, HSC70, and HSP40 (179, 220, 221).   In this study, GA/RA treatment of 
PriessGAD cells resulted in increased expression of HSP70, HSP90, HSC70, and HSP40 
suggesting that GA/RA treatment does induce a stress response in B cells (Fig. 12).  
Studies suggest that cell stress such as heat shock can also promote changes in Ag 
processing and MHC class II presentation of some exogenous and endogenous Ags by B 
cells (222).  Yet, heat shocking PriessGAD cells failed to affect MHC class II 
presentation of endogenous GAD Ag, exogenous HSA Ag, or HSA peptide (Fig. 14).  
These results indicate that while cellular RA and GA treatment induces a stress response 
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and upregulated overall HSP/HSC expression in B cells, such cellular stress alone does 
not contribute to the observed decrease in MHC class II presentation of GAD Ag 
associated with pharmacological inhibition of HSP90. This suggests that HSP90 has a 
distinct role in MHC class II presentation of GAD Ag.    
 
While the individual functions of HSP90 α and β isoforms have been dissected in terms 
of MHC class I presentation, this work marks a first step in addressing the role of these 
HSP90 isoforms in MHC class II presentation.  HSP90α alone was found to modulate Ag 
processing for MHC class I presentation (141).  Using HSP90 α and β specific siRNA to 
modulate HSP90 protein abundance revealed both isoforms were involved in MHC class 
II presentation of exogenous and endogenous GAD (Figs. 22, 24A, and 24B).  These two 
isoforms may have distinct rather than redundant roles in the Ag processing and 
presentation pathway.  As previously mentioned, HSP90 purifies as a dimer, and in vivo, 
dimerization is required for HSP90 function (260).  Recent studies indicate that HSP90α 
and HSP90β primarily dimerize as homodimers, but heterdimerization does occur (174).  
While studies here indicate that both HSP90α and HSP90β are highly expressed in B 
cells, it remains unknown what form of dimers are primarily found in these cells.  The 
composition of HSP90 dimers in APCs may also influence Ag processing for MHC class 
II presentation.   
 
Potential steps where HSP90 regulates the MHC class II pathway of Ag presentation 
It is interesting that inhibition of HSP90 affects both endogenous and exogenous 
presentation of GAD Ag.  Analysis of MHC class II presentation of short synthetic GAD 
peptides failed to reveal a role for HSP90 in the cell surface loading of MHC class II 
molecules or B-T cell interactions.  Thus, HSP90 likely exerts its effect on intracellular 
GAD Ag processing or via unfolding GAD to facilitate MHC class II binding to antigenic 
epitopes.  The pathways of exogenous and endogenous MHC class II presentation for 
GAD Ag are distinct yet converge with shared processing in endosomal and lysosomal 
compartments (Figs. 2 and 3).  This leads to speculation as to exactly where HSP90 
modulates GAD processing and presentation.  Studies here examined whether HSP90 
 115 
affects GAD Ag presentation at one of the shared steps found within the classical and 
alternate MHC class II presentation pathways.       
 
MHC class II expression and dimer formation 
One shared step is loading of MHC class II complexes with peptides within endosomal 
compartments.  This results in both SDS stable MHC class II dimers as well as unstable 
dimers.  In murine macrophages, HSP90 overexpression has been shown to enhance 
MHC class II dimer stability while GA and RA treatments decrease dimer stability (142).  
Both HSP90 overexpression and inhibition were reported not to alter surface and total 
MHC class II protein expression in these murine cells (142).  Yet, no change in MHC 
class II expression or dimer stability was seen with a reduction in HSP90 function in 
human B cell lines (Figs. 15, 16, 21, and 44).  While HSP70 was shown to interact with 
HLA-DR molecules, it is unknown whether HSP90 can directly interact with HLA-DR 
molecules (209).  Coimmunoprecipitation studies using extracts from human B cells will 
determine whether HSP90 interacts with MHC class II molecules.  In PriessGAD cells, 
HSP90 inhibition by either GA/RA or HSP90α or HSP90β siRNA did not alter MHC 
class II expression or dimerization (Figs. 15, 16, and 21).  Thus, the decrease in MHC 
class II GAD Ag presentation observed with GA or RA treatment is not due to alterations 
in MHC class II expression or dimer stability in B cells (Figs. 8, 10 A and B, 22, and 24 
A and B).  Moreover, GAD peptide presentation was unaffected by HSP90 inhibition 
again suggesting no change in MHC class II surface expression or ligand loading (Figs. 
10 C and D and 24 C and D).  While future studies such as co-immunoprecipitation 
experiments can determine if HSP90 associates with other components of the MHC class 
II pathway, the current study suggests that HSP90 is not modulating MHC class II 
presentation by altering MHC class II protein expression or display at the cell surface.   
 
Ii processing and HSP90  
The role of HSP90 in Ii processing was tested using small molecule inhibitors as well as 
HSP90 specific siRNA.  Inhibition of HSP90α and HSP90β expression by siRNA in 
PriessGAD cells did not affect Ii chain processing in B cells (Fig. 30).  However, 
leupeptin induced LIP accumulation was reduced by GA/RA treatment (Fig. 29).  With 
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both siRNA or pharmacological inhibition of HSP90, surface and total expression of 
CLIP and Ii were unchanged (Figs. 27 and 28).  The expression and function of HLA-
DM and HLA-DO were also found to be unaffected by HSP90α and HSP90β inhibition 
(Fig. 33).  While the mRNA expression for several cathepsins was unaffected by RA/GA 
treatment, cathepsin S, B, and L activity was altered (Figs. 31 and 32).  As previously 
stated, cathepsins S and L have been shown to be essential proteases catalyzing Ii 
processing and Ag presentation.  The enhanced activity of these proteases could reflect a 
change in endosomal and lysosomal pH or reflect the cellular stress induced by GA/RA 
treatment of the cells.  Still, the effect of GA/RA on cathepsin activity failed to fully 
explain the overall affect on MHC class II presentation of GAD Ag.  While the profile of 
Ii fragments found in cells treated with GA/RA was similar to control cells or cells 
treated with HSP90 siRNA, we did note less of the Ii LIP fragment with GA/RA 
treatment.  This could reflect a change in the kinetics of Ii processing, which could be 
further tested by radiolabeling studies in the future.  Notably cellular MHC class II 
dimers and a final Ii fragment CLIP was not altered by GA/RA.  Therefore, I propose that 
HSP90 functions at an earlier step in the MHC class II pathways, prior to the involvement 
of these conserved events in the MHC class II pathway.   
  
Potential roles for HSP90 inside and outside of cells 
While HSP90 is located primarily in the cytoplasm of cells, a study in B cells found that 
heat stress induced enrichment of HSPs including HSP90 in exosomes which are released 
from cells (229).  HSP70, which can associate in the cytoplasm with HSP90, is secreted 
by tumor cells through a pathway involving lysosomal endosomes (197).  Notably, 
another intracellular chaperone, HSC70, is found both in the cytoplasm and 
endosomes/lysosomes with studies suggesting it translocates into the endosomal network 
in an ATP-dependent process (166).  Whether HSP90 uses a similar pathway to access 
the endosomal network is unknown.  Several studies have suggested peptide-HSP90 
complexes released by tumors can promote MHC class I presentation (137, 144, 223).  
Islet cell stress including exposure to cytokines such as IL-1β is known to induce HSP90 
expression prior to cell death (184).  Western immunoblotting of concentrated 
conditioned media from PriessGAD cells failed to detect HSP90 released from these cells 
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(Fig. 36).  Yet, we cannot rule out the retention of HSP90 in endosomes and lysosomes of 
these cells where it may intersect exogenous Ags such as GAD.  Pre-complexing purified 
HSP90 with exogenous GAD in vitro prior to addition to Priess cells slightly enhanced 
GAD presentation (Fig. 37).  While this enhancement was modest, this could be due to 
the lack of additional co-factors needed for cellular uptake or functional folding of this 
purified HSP90.  Taken together, these studies suggest that HSP90 may not be accessing 
endo/lysosomes via extracellular secretion and re-entry, but rather by direct access into 
those vesicles from the cytoplasm (Fig. 51).  Further studies are needed to determine if 
and how HSP90 is translocated directly into endo/lysosomes and how the regulation of 
HSP90 compartmentalization might influence Ag presentation.  Also, whether HSP90 is 
found in the endosomes and lysosomes of all cells or only APCs has not been explored.   
 
In the cytoplasm, HSP90 may function to chaperone endogenous GAD Ag for processing 
by cytoplasmic proteases such as the proteasome or calpain (Fig. 52).  This is supported 
by the observation that HSP90 is associated with cytoplasmic GAD within cell extracts 
(Fig. 17).  GAD Ag has been shown to be ubiquitinated, and previous studies from our 
lab have determined that GAD Ag MHC class II presentation of endogenous GAD Ag is 
dependent upon the protease activity of the cytoplasmic proteasome and calpain (67).  
Moreover, HSP90 is linked to the proteasome via its cofactors such as HSP70.  
Radiolabeling and immunoprecipitation experiments could be used to determine whether 
HSP90 inhibition alters GAD processing in B cells.  Moreover, co-immunoprecipitation 
studies could also assess whether GAD-HSP90 association is affected by treatment of 
PriessGAD cells with specific proteasomal and calpain inhibitors.   
 
Based on our current studies, one also cannot rule out a role for HSP90 in the 
translocation of GAD peptides into lysosomes.  Previous studies indicate that HSC70 
plays a key role in cytoplasmic GAD peptide translocation and subsequent MHC class II 
presentation (85).  These studies and work by others indicate that HSC70 facilitates 
peptide transport into the lysosomes (85, 162).  Our lab has previously shown in B cells 
that altering HSC70 expression can regulate MHC class II presentation of several 
cytoplasmic autoantigens leading one to deduce that CMA can regulate immunity (85).  
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In B cells, HSP90 primarily functions as part of several cytoplasmic multi-chaperone 
complexes containing HSPs such as HSC70 (152, 167, 175, 176).  It is unknown whether 
HSP90 interacts directly with HSC70 to help chaperone antigenic peptide fragments to 
lysosomes or HSP90 releases peptides to HSC70.  Future studies will be needed to 
determine whether selective HSP90α and HSP90β inhibition affects the translocation and 
MHC class II presentation of GAD peptides in the cytoplasm of B cells.  As one 
approach, purified HSP90 could be complexed with GAD peptides prior to 
electroporation into the cell’s cytoplasm to determine if this complex enhances peptide 
translocation and presentation.  
 
The current study supports a role for HSP90 in regulating MHC class II presentation of 
both exogenous and endogenous GAD Ag by human B cells.  Both pharmacological and 
siRNA targeted disruption of HSP90 specifically inhibited GAD presentation by MHC 
class II molecules, yet failed to perturb MHC class II presentation of other Ags.  Both 
HSP90 α and β isoforms were found to be involved in GAD Ag presentation by MHC 
class II molecules.  While HSP90 appears to function at the step of Ag binding to 
promote processing and presentation, future research will be needed to explore the exact 
sites of HSP90 action.  A working model of how HSP90 may function as a chaperone in 
the MHC class II pathways of exogenous and endogenous presentation is depicted in 
Figures 50 and 51 respectively.  Direct translocation of HSP90 from the cytosol to 
endo/lysosomes may allow HSP90 to gain access to exogenous Ags with HSP90 





Figure 50.  A working model of HSP90 and MHC class II presentation of exogenous 
GAD Ag.  HSP90 may be translocating from the cytosol to endosomes and/or 
lysosomes.  In these vesicles, HSP90 may interact with internalized, exogenous 
GAD Ag and chaperone its degradation into antigenic peptide fragments.    
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Likewise, cytoplasmic HSP90 may chaperone cytoplasmic Ags to proteases such as the 
proteasome or calpain for degradation into antigenic peptides.  The resulting peptides 
might be further chaperoned by HSP90 or transit via HSC70 into the lysosomes for 




Figure 51.  A working model of HSP90 and MHC class II presentation of 
endogenous GAD Ag. HSP90 may function as a chaperon to GAD Ag pre- and 
post-degradation by the proteasome or calpain.  HSP90 may bind native, 
endogenous GAD Ag and chaperone GAD Ag to the proteasome or calpain for 
degradation.  The binding of HSP90 to GAD Ag also protect this Ag from 
premature degradation by other proteases.  HSP90 may also bind to GAD peptide 
fragments generated by cytoplasmic proteases and target them to lysosomes via 
interacting with HSC70 and Lamp2.  Within the lysosomes, GAD peptide 
fragments may be further trimmed by lysosomal proteases prior to loading onto 
MHC class II molecules. This may also be mediated by intralysosomal HSPs such 
as HSP90.   
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Together, these observations reveal a novel function for HSP90 isoforms and suggest 
these HSPs may regulate the development of T cell responses to self and potentially 
foreign Ags.  This may prove crucial to understanding the initiation events and 
pathogenesis of autoimmunity.  Further understanding of the role of HSP90 isoforms in 
GAD Ag processing and presentation by MHC class II molecules may also prove useful 




HSP70 as a potential player in regulating MHC class II presentation of select 
antigens 
Studying the role of HSP90 in MHC class II presentation revealed a potential 
requirement for HSP70 in the presentation of select Ags.  HSP70 has been shown to 
perform a variety of chaperone functions including stabilizing newly synthesized or 
unfolding polypeptides in the cytoplasm, facilitating the translocation of nascent protein 
chains across membranes, mediating assembly or disassembly of multimeric protein 
complexes, and targeting proteins for degradation within lysosomes (187-189).  
Additional studies indicate that HSP70 may play a role in MHC class II presentation of 
exogenous Ags.  Studies have detected extracellular HSP70:peptide complexes in MHC 
class II  enriched compartments after receptor-mediated endocytosis (208).  In contrast to 
HSP90, HSP70 has been suggested to interact with MHC class II molecules (209).  
Studies also suggest HSP70 mediated enhancement of MHC class II restricted peptide 
presentation (209, 231).  And relevant to autoimmunity, HSP70 has been shown to 
promote myelin autoantigen presentation by MHC class II molecules (139).  The current 
study suggests that HSP70 not only affects the presentation of select exogenous Ags, but 
also select endogenous Ags.   
 
HSP70 has been well studied as a key player in amyloidosis, a group of diseases 
characterized by the assembly of protein fibrils that are deposited extracellulary in 
various organs and tissues.  Rarely are these fibrils deposited intracellularly, but a mutant 
Ig kappa light chain protein, SMA, does aggregate within the cytoplasm of cells.  Studies 
indicate that HSP70 interacts with SMA and plays an important role in its processing and 
aggregation.  Specifically, overexpression of HSP70 has been shown to decrease the 
aggregation and promote proteasomal degradation of SMA (207).  Therefore, it is 
suggested that HSP70 can regulate intracellular SMA fibril accumulation. Studies here 
show also that peptides from endogenous SMA can be presented by MHC class II 
molecules (Fig. 38).  In FrevSMA cells, GA/RA treatment induced a stress response with 
increased HSP40 and HSP70 protein expression (Fig. 41).  The expression of HSP70 was 
increased 7 to 10 fold in cells treated with GA/RA.  Heat shock of FrevSMA cells 
induced HSP expression comparable to GA/RA treatment (Fig. 42).  While heat shock 
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alone did not affect MHC class II presentation of endogenous and exogenous GAD, heat 
shock treatment of FrevSMA cells enhanced MHC class II presentation of endogenous 
SMA (Figs. 15 and 43).  Since both GA/RA treatment and heat shock enhanced MHC 
class II presentation of SMA, inhibition of HSP90 cannot explain the observed enhanced 
presentation of SMA protein.  Yet common to both these treatments was the induction of 
HSP70 expression.  By contrast, HSP40 expression was only slightly enhanced compared 
to HSP70 expression.  These results together with the previous studies indicating HSP70 
as a chaperone for SMA, suggest that the enhanced MHC class II presentation of SMA is 
due to the enhanced HSP70 expression.  These results at present only indirectly link 
HSP70 to MHC class II presentation of SMA, thus further studies using HSP70 specific 
siRNA and HSP70 overexpressing plasmids are needed to confirm a role for HSP70 in 
cytoplasmic Ag presentation.   
 
Interestingly, GA/RA treatment induced ER stress as indicated by significantly enhanced 
grp94 and BiP protein expression in FrevSMA cells, but not PriessGAD cells (Figs. 34, 
35, and 45).  The induced ER stress may impact and promote SMA degradation and 
HSP70 chaperone activity.  SMA is transported into the ER and fails to exit to the Golgi, 
but rather is retained in the ER and translocated to the cytosol for proteasomal 
degradation (207, 261-264).   As previously described, both grp94 and BiP play roles in 
both protein folding in the ER and ERAD.  GA and RA can inhibit cytoplasmic HSP90 as 
well as grp94 in the ER. With misfolded SMA in the ER, ER stress may be induced 
coupled with grp94 loss of function.  Moreover, previous studies indicate that BiP can 
bind to SMA (207, 230).  Enhanced grp94 and BiP expression within the ER may result 
and enhance SMA translocation from the ER into the cytosol.  There cytosolic HSP70 
could further assist in chaperoning SMA to the proteasome for degradation.  Increased 
SMA degradation could lead to an increase in the SMA peptides that could be presented 
by MHC class II molecules.  Further studies using grp94 and BiP inhibitors could be 
carried out to examine the role of ER stress in SMA translocation, degradation, and MHC 
class II presentation.  Further studies using siRNA to block HSP70 expression would be 
important.      
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Treatment of Frev cells with GA/RA not only enhanced MHC class II presentation of 
endogenous SMA, but also MHC class II display of peptides, kappa I and kappa II from 
exogenous Ig kappa light chain (Fig. 39).  While the presentation of synthetic exogenous 
HSA or GAD peptides was unaffected by GA/RA treatment, this treatment did enhance 
the MHC class II presentation of exogenous kappa I and kappa II peptides (Fig. 11 C and 
D, 12 C and D, and 40).  As previously stated, HSP70 has been extensively studied as a 
chaperone for exogenous Ags for both exogenous and endogenous presentation.  
Moreover, peptides were more efficiently presented by MHC class II molecules when 
precomplexed with HSP70 (209).  In response to stress, HSP70 is secreted from a variety 
of cell types via an undefined pathway (190-195).   Under normal conditions HSP70 is 
not secreted by FrevSMA cells, and GA/RA treatment did not induce HSP70 secretion 
(Fig. 46).  Thus, secreted HSP70 due to GA/RA treatment is likely not an explanation for 
enhanced MHC class II presentation of exogenous Ig kappa Ag and kappa I and kappa II 
peptides.  Additionally, this enhancement seems to be Ag and peptide specific as MHC 
class II presentation of GAD peptide, HSA Ag, and HSA peptide was not unaffected by 
GA/RA treatment.  Further studies are needed to examine the role of HSP70 in the 
enhancement of MHC class II presentation of select Ags.      
 
While this work implicates HSP70 as a potential modulator of MHC class II presentation 
of select endogenous and exogenous Ags, further research is needed to confirm these 
findings and determine specifically how HSP70 modulates these pathways.  However, 
working models of HSP70 chaperone function within the MHC class II pathway of 
endogenous and exogenous presentation are represented in Figures 52 and 53 
respectively.  In FrevSMA cells, endogenous HSP70 may chaperone SMA from the ER 
to the proteasome for proteasomal degradation.  HSP70 may also bind SMA peptide 
fragments and chaperone them to the HSC70/lamp2 complexes at the lysosomal surface 





Figure 52. A Working Model of HSP70 and MHC Class II Presentation of 
Endogenous SMA Ag.  Endogenous SMA is translocated from the ER to the 
cytosol via ER chaperone proteins grp94 and BiP.  In the cytosol, HSP70 may 
bind to cytosolic and chaperone it to the proteasome for degradation into antigenic 
peptide fragments.  HSP70 binding to SMA may also protect it from premature 
protein degradation.  Upon proteasomal degradation, SMA peptide fragments may 
also be recognized by HSP70 and targeted to the HSC70/Lamp2 complex for 
translocation into lysosome.  HSP70 may also be translocated directly from the 
cytosol into the lysosomes.  Here, HSP70 may mediate further trimming of SMA 
peptides and/or stabilize them prior to loading onto MHC class II molecules.   
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For MHC class II presentation of exogenous Ags, HSP70 may gain access to 
endo/lysosomes and facilitate Ag proteolysis into peptide fragments.  Additionally, 
HSP70 may facilitate peptide loading onto MHC class II molecules (Fig. 53). 
 
Figure 53.  A working model of HSP70 and MHC class II presentation of exogenous 
Ig kappa Ag.  HSP70 may be directly translocated from the cytosol to endosomes 
and/or lysosomes.  Within these vesicles, HSP70 may chaperone internalized, Ig 
kappa Ag and guide its degradation into antigenic peptide fragments. HSP70 may 
also assist in the peptide loading of MHC class II molecules. 
 
HSP70 has been shown to perform various intra- and extracellular functions.  While 
studies implicate HSP70 as a chaperone for MHC class I and class II presentation of 
exogenous Ags, this study suggests a novel role for HSP70 in MHC class II presentation 
of endogenous Ags.  Moreover, this work suggests that HSP70 functions as a chaperone 
for only select endogenous and exogenous Ags.  Research has linked HSP70 chaperone 
function to protein folding diseases such as amyloidosis and autoimmune diseases such as 
multiple sclerosis (139, 207).  Understanding the role of HSP70 in MHC class II 
presentation of select Ags may be crucial in understanding the pathogenesis of these 
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